Original Article
Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons
N Engl J Med 2004; 351:451-459July 29, 2004
- Abstract
Background
Chronic hepatitis C virus (HCV) infection is a cause of major complications in persons who are also infected with the human immunodeficiency virus (HIV). However, the treatment of HCV infection in such persons has been associated with a high rate of intolerance and a low rate of response. We conducted a multicenter, randomized trial comparing peginterferon plus ribavirin with interferon plus ribavirin for the treatment of chronic hepatitis C in persons coinfected with HIV.
Methods
A total of 66 subjects were randomly assigned to receive 180 μg of peginterferon alfa-2a weekly for 48 weeks, and 67 subjects were assigned to receive 6 million IU of interferon alfa-2a three times weekly for 12 weeks followed by 3 million IU three times weekly for 36 weeks. Both groups received ribavirin according to a dose-escalation schedule. At week 24, subjects who did not have a virologic response (those who had an HCV RNA level greater than or equal to 60 IU per milliliter) underwent liver biopsy, and medications were continued in subjects with either a virologic response or histologic improvement.
Results
Treatment with peginterferon and ribavirin was associated with a significantly higher rate of sustained virologic response (an HCV RNA level of less than 60 IU per milliliter 24 weeks after completion of therapy) than was treatment with interferon and ribavirin (27 percent vs. 12 percent, P=0.03). In the group given peginterferon and ribavirin, only 14 percent of subjects with HCV genotype 1 infection had a sustained virologic response (7 of 51), as compared with 73 percent of subjects with an HCV genotype other than 1 (11 of 15, P<0.001). Histologic responses were observed in 35 percent of subjects with no virologic response who underwent liver biopsy.
Conclusions
In persons infected with HIV, the combination of peginterferon and ribavirin is superior to the combination of interferon and ribavirin in the treatment of chronic hepatitis C. These regimens may provide clinical benefit even in the absence of virologic clearance. The marked discrepancy in the rates of sustained virologic response between HCV genotypes indicates that strategies are needed to improve the outcome in persons infected with HCV genotype 1.
Media in This Article
Figure 1
Study Design.Figure 2
Predictive Value of an Early Virologic Response.Article Activity
- Article
Coinfection with hepatitis C virus (HCV) is common among persons infected with the human immunodeficiency virus (HIV), with a prevalence ranging from 4 to 92 percent depending on the underlying risk factors. Since the introduction of potent antiretroviral therapy, liver disease due to HCV coinfection has become a major source of mortality among HIV-infected persons.1-3 The progression of liver disease appears to be accelerated in such persons.4
Treatment regimens based on interferon and ribavirin are recommended for chronic hepatitis C but pose special concerns in persons coinfected with HIV, particularly those who are receiving antiretroviral therapy. Common side effects of treatment, such as depression, anemia, and lymphopenia, may be exacerbated. Ribavirin may interfere with thymidine analogues such as zidovudine and stavudine5,6 and may potentiate the toxic effects of didanosine.7 To date, the few studies examining the effect of interferon and ribavirin in patients coinfected with HCV and HIV have had disappointing rates of sustained virologic response and high rates of intolerable side effects.8,9 More recently, the use of peginterferon with ribavirin has significantly improved the rates of virologic response in patients with HCV infection alone.10,11 We therefore conducted a multicenter, randomized, controlled trial comparing peginterferon plus ribavirin with interferon plus ribavirin in the treatment of HCV infection in subjects coinfected with HIV.
Methods
Selection of Subjects
The Adult AIDS Clinical Trials Group (ACTG) A5071 was a prospective study conducted at 21 ACTG sites in the United States. HIV-infected subjects 18 years of age or older were eligible to participate if they had a confirmed diagnosis of chronic hepatitis C, as defined by an HCV RNA level of more than 600 IU per milliliter, and had not previously been treated with interferon alfa. A liver biopsy demonstrating abnormal histologic findings consistent with the presence of chronic hepatitis C was required within 48 weeks before study entry. Subjects with cirrhosis were eligible provided they had no evidence of hepatic decompensation (i.e., ascites, encephalopathy, jaundice, hypoalbuminemia, or coagulopathy). Subjects who had normal or elevated serum alanine aminotransferase levels were eligible.
Subjects were stratified into two groups according to their history of HIV therapy: subjects whose antiretroviral-therapy regimen had been stable for at least 12 weeks with CD4 cell counts of more than 100 per cubic millimeter and less than 10,000 copies of HIV type 1 (HIV-1) RNA per milliliter, and subjects with CD4 cell counts of more than 300 per cubic millimeter who had never received antiretroviral agents and who were not planning to begin HIV therapy during the trial. Subjects were excluded if they had clinically significant anemia, neutropenia, or thrombocytopenia; renal disease; positive tests for hepatitis B surface antigen; uncontrolled cardiopulmonary disease; poorly controlled psychiatric disease; or an active HIV-related opportunistic infection.
Study Design
Figure 1Figure 1
Study Design. shows the design of the study. Subjects were randomly assigned to receive either 180 μg of peginterferon alfa-2a subcutaneously weekly plus ribavirin (600 mg per day for 4 weeks, 800 mg per day for 4 weeks, and then 1000 mg per day for the remainder of the study) or 6 million IU of interferon alfa-2a subcutaneously three times weekly for 12 weeks followed by 3 million IU subcutaneously three times weekly for the remainder of the study plus the same regimen of ribavirin used in the first group. The dose of ribavirin was increased in a stepped fashion to reduce the treatment-limiting anemia previously observed in persons coinfected with HCV and HIV.8 At randomization, stratification variables included the HCV genotype (genotype 1 vs. other genotypes) and antiretroviral-therapy status (current antiretroviral therapy vs. no antiretroviral therapy). The study was designed to have a statistical power of 80 percent (with a two-sided alpha value of 0.05) to detect an absolute difference in the rate of virologic response between groups of 30 percent. The target sample size of 132 was adjusted for a group-sequential design.An efficacy and safety assessment was performed in all subjects at week 24 to determine whether they could continue to participate. Subjects who had a virologic response (defined as an HCV RNA level of less than 60 IU per milliliter) continued treatment until week 48, at which time a liver biopsy was performed. Subjects who had no virologic response at week 24 were required to undergo liver biopsy at that time. Subjects who had a histologic response, as defined by an improvement in the total hepatic activity index12 of at least two points, as judged by a central pathologist, were also permitted to continue treatment until week 48. Subjects who did not have a virologic response at week 24 and subjects who either had no histologic response or did not undergo liver biopsy stopped taking the study drug. Subjects were followed for an additional 24 weeks after the completion of therapy. HCV RNA levels were assessed at entry and at weeks 4, 8, 12, 36, and 60 with the use of a quantitative RNA assay (lower limit of detection, 600 IU per milliliter, Roche Cobas Amplicor 2.0) and at weeks 24, 48, and 72 with the use of a qualitative RNA assay (lower limit of detection, 60 IU per milliliter, Roche Cobas Amplicor 2.0).
HCV genotyping was performed on all subjects at entry with the use of a line-probe assay (LiPA, Innogenetics). Results were reported as genotype 1 or a genotype other than 1.
The institutional review boards of the participating sites approved the protocol, and all subjects provided written informed consent. An external data and safety monitoring board reviewed the study design and the results of one interim analysis.
The study was funded by the National Institutes of Health. The drugs and diagnostic kits for the detection of HCV RNA were provided by Roche Laboratories. The study investigators had access to all of the study data, took responsibility for the accuracy of the analysis, and had full and independent authority over the preparation of the manuscript and decisions concerning publication.
Assessment of Efficacy and Safety
Because of concern about the safety of administering these drugs to subjects who were coinfected with HIV, we used the primary end points of virologic response and safety at week 24. Secondary end points included a sustained virologic response, defined by an HCV RNA level of less than 60 IU per milliliter 24 weeks after the completion of therapy, allowing a 6-week window for the sample; a virologic response at the end of treatment, as defined by an HCV RNA level of less than 60 IU per milliliter at the completion of therapy; an early virologic response, as defined by the clearance of HCV RNA or a reduction in HCV RNA levels by more than 2 log (on a base-10 scale) IU per milliliter at 12 weeks of treatment; a histologic response; changes in the control of HIV disease, as defined by changes in the CD4 cell count, percentage of CD4 cells, and HIV-1 RNA levels; or development of an AIDS-defining illness. HIV-1 RNA was assessed with the use of an assay (Roche Cobas Amplicor 2.0) with a lower limit of detection of 50 copies per milliliter. All data were analyzed according to the intention to treat.
Safety was assessed at weeks 1, 2, and 4 and every 4 weeks thereafter and 12 and 24 weeks after the discontinuation of the study drug. Specific end points were the incidence of grade 3 (severe) or 4 (life-threatening) adverse events13 and the premature discontinuation of treatment.
Subjects who discontinued treatment prematurely because of intolerance to the study drug were encouraged to remain in the study. Stepwise reductions in the doses of peginterferon to 135, 90, or 45 μg weekly and reductions in ribavirin doses to 600 mg per day were permitted to manage adverse events or abnormalities in laboratory values that reached predetermined thresholds of severity. If the adverse event resolved or improved, a return to the initial dosing level was permitted unless the subject had received the reduced dose for more than four weeks. Subjects were withdrawn from treatment if they missed three or more consecutive doses or at the discretion of the investigator. The use of supplemental hematopoietic growth factors (epoietin alfa and filgrastim) was permitted.
Statistical Analysis
Associations between dichotomous variables were evaluated with Fisher's exact test. Associations involving ordered categorical data or continuous data were evaluated with a Wilcoxon test adjusted for ties. Univariate- and multicovariate-adjusted P values for the association of the virologic response at week 24 with covariates were evaluated with logistic regression stratified according to the HCV genotype and HIV treatment history. All P values are two-sided. Univariate analyses of sustained virologic response were performed with log-rank tests, and multicovariate analyses with proportional-hazards regression. Because of the limited sample size and because sustained virologic response was not a primary objective, these tests were not stratified according to the group or the HCV genotype. The proportion of subjects who continued to have sustained virologic response was estimated with the use of the life-table method.
Results
Baseline Characteristics
A total of 134 subjects were enrolled between December 2000 and June 2001. One subject was excluded from analyses because he did not meet the entry criteria; he did not receive treatment. Table 1Table 1
Baseline Characteristics of the Subjects. depicts the baseline characteristics of the 133 eligible subjects. All received at least one dose of study medication. The pretreatment characteristics of the subjects in the two groups were similar, including age, sex, race or ethnic group, and performance status. Eighty-six percent of subjects were receiving stable antiretroviral therapy; 60 percent of subjects had fewer than 50 copies of HIV-1 RNA per milliliter. The median CD4 cell counts were nearly 500 per cubic millimeter. The median HCV RNA levels were high, with levels exceeding 106 IU per milliliter in 82 percent of subjects. Seventy-eight percent had HCV genotype 1 infection, and 67 percent had abnormal alanine aminotransferase levels. Baseline histologic findings were similar in the two groups. Ten percent of subjects had evidence of cirrhosis (as defined by a fibrosis stage of 5 or 6).Virologic Response
The rates of virologic response at week 24 and at the end of treatment were higher in the group given peginterferon and ribavirin than in the group given interferon and ribavirin (Table 2Table 2
Rates of Virologic Response.). At week 24, 44 percent of subjects in the group given peginterferon and ribavirin had a virologic response, as compared with 15 percent of those in the group given interferon and ribavirin (P<0.001), and the rates of virologic response at the end of treatment were 41 percent and 12 percent, respectively (P<0.001) (Table 2).Receipt of peginterferon and ribavirin was associated with a significantly higher rate of sustained virologic response (27 percent, vs. 12 percent in the group given interferon and ribavirin; P=0.03). As with HCV monoinfection, there was a significant disparity in response rates in both groups between subjects infected with HCV genotype 1 and those infected with other HCV genotypes. For those with genotype 1 infections, the rate of sustained virologic response was only 14 percent in the group given peginterferon and ribavirin and 6 percent in the group given interferon and ribavirin, whereas for those infected with other HCV genotypes (predominantly genotypes 2 and 3), the respective rates of sustained virologic response were 73 percent and 33 percent (P<0.001 for the comparison with genotype 1 infections). The observed decrement in the rate of sustained virologic response from the end-of-treatment virologic response in the group given peginterferon and ribavirin was attributable to a high relapse rate among those with HCV genotype 1 infection.
Predictors of a Sustained Virologic Response
Receipt of peginterferon and ribavirin, an HCV genotype other than 1, the absence of prior injection-drug use, a detectable level of HIV-1 RNA at entry, and a Karnofsky score of 100 were predictive of a sustained virologic response in univariate analysis (Table 3Table 3
Predictors of a Sustained Virologic Response.). In multivariate analysis, all of these variables but the Karnofsky score independently predicted a sustained virologic response. The baseline CD4 cell count, percentage of CD4 cells, age, race or ethnic group, body weight, HCV RNA level, use or nonuse of any antiretroviral therapy, use or nonuse of protease inhibitors, baseline HIV RNA level, use or nonuse of supplemental growth factors, and pretreatment histologic findings were not predictive of a sustained virologic response.Early Virologic Response
Of the 106 subjects in whom HCV RNA levels were measured at week 12 (Figure 2Figure 2
Predictive Value of an Early Virologic Response.), 43 (41 percent) had an early virologic response. Twenty-two of these 43 subjects (51 percent) had a sustained virologic response. In contrast, none of the 63 subjects who did not have an early virologic response had a sustained virologic response (negative predictive value, 100 percent).Histologic Response
Among the subjects with no virologic response at week 24, 45 of 57 subjects in the group given interferon and ribavirin (79 percent) underwent liver biopsy, as did 26 of 37 subjects in the group given peginterferon and ribavirin (70 percent). A histologic response was observed in 25 of these 71 subjects (35 percent), 36 percent of such subjects in the group given interferon and ribavirin and 35 percent of such subjects in the group given peginterferon and ribavirin. The magnitude of the reduction in HCV RNA levels among subjects with a histologic response did not differ from that among those without a histologic response, indicating that a partial virologic response did not predict histologic improvement.
Among the 39 subjects with a virologic response at week 24, 27 underwent a biopsy at week 48. Fourteen of these 27 subjects (52 percent) had a histologic improvement, 11 (41 percent) had no change, and 2 (7 percent) had worsening disease.
Safety and Adverse Events
Eight subjects in each group (12 percent) were prematurely withdrawn from treatment because of abnormalities in laboratory values or other adverse events, and the rates were similar to the rates of premature withdrawal in studies of subjects with HCV monoinfection who received similar treatments.12,13 Of the 16 such subjects, 3 declined further participation and 1 died of causes unrelated to HCV infection or treatment. The remaining 12 were withdrawn from the study because of either neuropsychiatric issues (primarily depression) or the need to manage multiple signs and symptoms and abnormal laboratory values. Similar numbers of subjects in each group had grade 2 or 3 influenza-like symptoms and grade 2 or 3 depression during treatment (Table 4Table 4
Adverse Events.). There were no significant differences between groups in the frequency of grade 2 or higher decreases in hemoglobin; such decreases occurred in few subjects. Neutrophil counts decreased in both groups, particularly during the first two weeks of treatment. Two subjects in the group given peginterferon and ribavirin discontinued therapy because of grade 4 neutropenia (defined as fewer than 500 neutrophils per cubic millimeter). In six others (three in each group), grade 4 neutropenia was successfully managed with a dose reduction, with or without the addition of hematopoietic growth factor. Grade 4 thrombocytopenia occurred in only one subject in the group given peginterferon and ribavirin.Although grade 2 or 3 elevations in lipase were observed in nine subjects in each group during the first 24 weeks, there was only one clinically significant episode of pancreatitis requiring hospitalization and the discontinuation of treatment at week 16. The subject was also receiving didanosine. Of the 18 subjects with lipase elevations of grade 2 or higher, only 4 were taking didanosine. A single grade 3 elevation in lactate was noted in one subject, but it did not require the discontinuation of treatment. One subject died of complications related to Hodgkin's disease; this event was thought to be unrelated to the study medications. There were no AIDS-defining illnesses.
Effects on the Control of HIV Disease
The median CD4 cell count fell from entry to week 24 in both groups (by 130 cells per cubic millimeter in the group given peginterferon and ribavirin and by 103 cells per cubic millimeter in the group given interferon and ribavirin, P=0.04); however, the percentage of CD4 cells actually increased in both groups (by 3.5 percent and 3.0 percent, respectively). For the subjects who continued treatment until week 48, the absolute CD4 cell count did not decrease further and returned to baseline 24 weeks after treatment was stopped.
A total of 119 subjects had data on HIV-1 RNA levels available at baseline and week 24. Fifty-four percent of subjects in the group given interferon and ribavirin and 52 percent of those in the group given peginterferon and ribavirin had undetectable levels of HIV-1 RNA at both times. Another 29 percent in each group had detectable levels of HIV-1 RNA at both times. Six percent of subjects in the group given interferon and ribavirin and 5 percent of those given peginterferon and ribavirin had undetectable levels at baseline and detectable levels of HIV-1 RNA at 24 weeks. Eleven percent and 14 percent, respectively, had initially detectable levels that were undetectable at 24 weeks.
Discussion
We conducted a multicenter, randomized, controlled trial of peginterferon and ribavirin and interferon and ribavirin in subjects who were coinfected with HCV and HIV. The combination of peginterferon and ribavirin was significantly more effective in achieving a sustained virologic response than was the combination of interferon and ribavirin. However, the rate of sustained virologic response with peginterferon and ribavirin therapy was considerably lower than the rates among patients with HCV monoinfection who received similar therapy,10,11 despite the relatively high CD4 cell counts in our cohort.
We observed an even more dramatic disparity in the response of different HCV genotypes than was observed in patients with HCV monoinfection. The rate of sustained virologic response after peginterferon and ribavirin in HIV-infected subjects with HCV genotype 2 or 3 infection approached historical rates in subjects with HCV monoinfection (which are 75 to 82 percent), but the rate of response to interferon and ribavirin was lower.10,11 However, there was a marked dropoff in the rate of sustained response among subjects with HCV genotype 1 and HIV infection, as compared with historical rates among subjects with HCV monoinfection (42 to 45 percent).10,11 Among subjects who received peginterferon and ribavirin, the large decrease in the rate of sustained virologic response was driven primarily by a high relapse rate in those with HCV genotype 1 infection. The use of peginterferon and ribavirin in patients coinfected with HCV genotype 1 and HIV should therefore be carefully weighed against this low projected rate of response.
There are several potential explanations for the diminished rates of antiviral response: HCV RNA levels are higher in subjects with HIV coinfection than in those with HCV monoinfection; the cumulative doses of ribavirin received in this dose-escalation regimen may have been, either because of the study design or because of dose reductions, insufficient to prevent relapse; and qualitative rather than quantitative defects in the cellular immune response may underlie the failure to clear HCV. Investigation of new treatment strategies, including use of dose-optimized ribavirin, will be required to improve response rates and decrease relapse rates among patients coinfected with HCV genotype 1 and HIV.
Adherence to treatment has been cited as a potentially important factor in determining the outcome. We did not specifically examine adherence, since detailed pill or injection counts were not performed. Although information regarding dose-modification events is available to us, the complex nature of the study design, in which only subjects with a virologic response or subjects with a histologic response but not a virologic response were permitted to continue therapy beyond 24 weeks (a total of 64 subjects), limits our ability to perform a meaningful analysis of the relationship between adherence and a sustained virologic response.
The rate of premature discontinuation of 12 percent was similar to the rates in studies of HIV-negative subjects with chronic hepatitis C10,11 and was perhaps lower than those in prior studies of interferon and ribavirin in subjects coinfected with HCV and HIV, in which dropout rates approached 30 percent.8,9 This favorable outcome may have been attributable to the dosing schedule for ribavirin, which was designed to maximize the retention of study subjects.
Furthermore, antiviral therapy for HCV had no adverse effect on the control of HIV disease. Interferon has broadly suppressive effects on leukocytes, and the finding of reduced CD4 cell counts was therefore not surprising; however, the percentage of CD4 cells actually increased, and HIV-1 RNA levels did not change appreciably during the study. Most important, no clinical progression of HIV to AIDS was observed during the study period.
The surprising finding that the presence of detectable HIV-1 RNA levels at entry was associated with a sustained virologic response to HCV therapy may reflect several factors: the enrollment of subjects with relatively preserved CD4 cell counts who had not received antiretroviral therapy or of subjects who had not been receiving antiretroviral therapy long enough to have complete virologic suppression and the association of HIV suppression with increases in HCV RNA.14 Alternatively, given that this finding was the result of an exploratory analysis of a secondary end point, it may represent a type I error. Confirmation in other studies will be important.
Because of the importance of the progression of liver disease in subjects who are coinfected with HCV and HIV, we also assessed histologic responses in both those with a virologic response and those without a virologic response. It is consistent with the observed effects of combination antiviral therapy on liver histologic findings that the majority of subjects with a virologic response had a histologic response. We also found that among subjects without a virologic response who underwent liver biopsy, over one third had histologic evidence of improvement, despite the absence of a significant decrease in HCV viremia. These data suggest that interferon-based therapy has benefits that are independent of its antiviral effects and support the need for investigation of maintenance strategies, especially among subjects coinfected with HCV and HIV who have moderate-to-advanced fibrosis. Maintenance therapy with interferon could be given for extended periods at doses that do not clear the virus but may halt or slow the progression of liver fibrosis, as has been done in subjects with HCV monoinfection.15 These data take on even greater relevance in the light of the low rates of response to interferon therapy in subjects coinfected with HCV genotype 1 and HIV.
Since the absence of markers of an early virologic response uniformly predicted the futility of treatment, early discontinuation of antiviral therapy at 12 weeks should be considered in patients with minimal or no fibrosis who do not have a reduction in HCV RNA levels by a factor of 100 from baseline. However, therapy should be continued in patients with more advanced disease, since the goal of treatment is slowing the progression of liver disease rather than eradicating the virus.
Supported by General Clinical Research Center grants (RR00046, RR00096, and RR00044) and a Center for AIDS Research grant (P30-AI27763D) from the National Institute of Allergy and Infectious Diseases and by grants (AI25868, AI27661, AI27670, AI27675, AI46370, AI25897, AI50410, AI046376, and AI27659) from the ACTG.
Dr. Andersen reports having received consulting fees from Tibotec; Dr. Chung grant support from Roche Laboratories and Schering-Plough; Dr. Peters lecture fees or grant support from Axcan, Gilead, Roche, and Schering-Plough; Dr. Robbins consulting fees, lecture fees, or grant support from Abbott, Agouron, Bristol-Myers Squibb, and GlaxoSmithKline; Dr. Sherman consulting fees, lecture fees, or grant support from Bristol-Myers Squibb, Hoffmann–La Roche, Intermune, PharmaResearch, and Schering-Plough; and Dr. Volberding consulting fees, lecture fees, or grant support from Gilead, Bristol-Myers Squibb, GlaxoSmithKline, OrthoBioTech, Pfizer, and Shire.
We are indebted to the following for their participation in the study: Amy Sbrolla, Harvard University, Massachusetts General Hospital (ACTG site A0101); Michael Scott and Elizabeth Race, University of Texas, Southwestern Medical Center (ACTG site A3751); Alex Chall, Jackie Kaufman, and Dickens Theodore, University of North Carolina (ACTG site A3201); Chris Hurley and Mary Shoemaker, University of Rochester Medical Center (ACTG site A1101); Richard Hutt and Charles Gonzalez, New York University, Bellevue (ACTG site A0401); Thomas Merigan, Debbie Slamowitz, and Jane Norris, Stanford University (ACTG site A0501); Diane Daria and Josette Robinson, University of Cincinnati (ACTG site A2401); James Richardson and Greta Clement, Indiana University Hospital (ACTG site A2601); Jolene Noel-Connor and Steven Chang, Columbia University (ACTG site A7802); Donna Mildvan and David J. Clain, Beth Israel Medical Center (ACTG site A2851); Nancy Hanks (Hawaii AIDS Clinical Research Program) and Scott Souza (Queen's Medical Center Hawaii AIDS Clinical Research Program), University of Hawaii (ACTG site A5201); M. Graham Ray and Gregory Fitz, University of Colorado Health Sciences Center (ACTG site A6101); Charles Bradley Hare and Joann Volinski, San Francisco General Hospital (ACTG site A0801); Margaret A. Fischl and Nancey Bathurst, University of Miami (ACTG site A0901); Michael Conklin and Judith Aberg, Washington University (ACTG site A2101); Joel Maslow and Rosanne Burke, University of Pennsylvania, Philadelphia (ACTG site A6201); Jack Stapleton and Julie Katseres, University of Minnesota (ACTG site A1501); Patrick Lynch and Robert Murphy, Northwestern University (ACTG site A2701); and Tari Gilbert and Gerald Moreno, University of California, San Diego, Antiviral Research (ACTG site A0701); to Roche Laboratories for providing the study drug and HCV RNA monitoring kits; and to Susan Breen for assistance in the preparation of the manuscript.
Source Information
From Massachusetts General Hospital, Boston (R.T.C., G.K.R., A.K.B.); Harvard School of Public Health, Boston (J.A., T.L.); the University of California, San Francisco, San Francisco (P.V., M.G.P.); the University of Cincinnati, Cincinnati (K.E.S.); Beth Israel Deaconess Medical Center, Boston (M.J.K.); the National Institute of Allergy and Infectious Diseases, Bethesda, Md. (B.A.); Frontier Science Technology and Research Foundation, Amherst, N.Y. (D.C.); Social and Scientific Systems, Rockville, Md. (T.N.); Roche Laboratories, Nutley, N.J. (G.H.); and the University of North Carolina, Chapel Hill (C.H.).
Address reprint requests to Dr. Chung at GRJ 825, GI Unit, Massachusetts General Hospital, Boston, MA 02114, or at rtchung@partners.org.
- References
References
1
Bica I ,McGovern B ,Dhar R , et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497
CrossRef | Web of Science | Medline2
Lesens O ,Deschenes M ,Steben M ,Belanger G ,Tsoukas CM . Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999;179:1254-1258
CrossRef | Web of Science | Medline3
Darby SC ,Ewart DW ,Giangrande PL , et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-1431
CrossRef | Web of Science | Medline4
Benhamou Y ,Bochet M ,Di Martino V , et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999;30:1054-1058
CrossRef | Web of Science | Medline5
Baba M ,Pauwels R ,Balzarini J ,Herdewijn P ,De Clercq E ,Desmyter J . Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother 1987;31:1613-1617
Web of Science | Medline6
Vogt MW ,Hartshorn KL ,Furman PA , et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-1379
CrossRef | Web of Science | Medline7
Lafeuillade A ,Hittinger G ,Chadapaud S . Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001;357:280-281
CrossRef | Web of Science | Medline8
Landau A ,Batisse D ,Van Huyen JP , et al. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000;14:839-844
CrossRef | Web of Science | Medline9
Zylberberg H ,Benhamou Y ,Lagneaux JL , et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000;47:694-697
CrossRef | Web of Science | Medline10
Manns MP ,McHutchison JG ,Gordon SC , et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965
CrossRef | Web of Science | Medline11
Fried MW ,Shiffman ML ,Reddy KR , et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
Full Text | Web of Science | Medline12
Ishak K ,Baptista A ,Bianchi L , et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699
CrossRef | Web of Science | Medline13
Division of AIDS table for grading severity of adult adverse experiences. Bethesda, Md.: National Institute of Allergy and Infectious Diseases, 1992.
14
Chung RT ,Evans SR ,Yang Y , et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002;16:1915-1923
CrossRef | Web of Science | Medline15
Shiffman ML ,Hofmann CM ,Contos MJ , et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-1172
CrossRef | Web of Science | Medline
- Citing Articles (342)
Citing Articles
1
S. Naggie, N. I. Rallon, J. M. Benito, J. Morello, S. Rodriguez-Novoa, P. J. Clark, A. J. Thompson, K. V. Shianna, E. Vispo, J. G. McHutchison, D. B. Goldstein, V. Soriano. (2012) Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes. Journal of Infectious Diseases 205:3, 376-383
CrossRef2
Mark S. Sulkowski. (2012) Hepatitis C virus-human immunodeficiency virus coinfection. Liver International 32, 129-134
CrossRef3
Kyong-Mi Chang. 2012. Immune Pathogenesis of Viral Hepatitis B and C. , 111-128.
CrossRef4
Marie-Louise Vachon, Ponni Perumalswami, Douglas T. Dieterich. 2011. Hepatobiliary Manifestations of Human Immunodeficiency Virus. , 1060-1082.
CrossRef5
Jama M. Darling, Stanley M. Lemon, Michael W. Fried. 2011. Hepatitis C. , 582-652.
CrossRef6
Kathryn N. Devlin, Assawin Gongvatana, Uraina S. Clark, Jesse D. Chasman, Michelle L. Westbrook, Karen T. Tashima, Bradford Navia, Ronald A. Cohen. (2011) Neurocognitive Effects of HIV, Hepatitis C, and Substance Use History. Journal of the International Neuropsychological Society1-11
CrossRef7
Xu Wang, Ting Zhang, Wen-Zhe Ho. (2011) Opioids and HIV/HCV Infection. Journal of Neuroimmune Pharmacology 6:4, 477-489
CrossRef8
Gail V. Matthews, Gregory J. Dore. 2011. HIV and Hepatitis C Co-Infection. , 177-184.
CrossRef9
Sanjay Bhagani. (2011) Current treatment for chronic hepatitis C virus/HIV-infected individuals. Current Opinion in HIV and AIDS 6:6, 483-490
CrossRef10
Andrew H. Talal, Ruei-Chi Liu, Marija Zeremski, Rositsa Dimova, Lorna Dove, Daniel Pearce, Tarek Hassanein, Leleka Doonquah, David Aboulafia, Jorge Rodriguez, Hector Bonilla, Jeffrey Galpin, Judy A. Aberg, Barbara Johnston, Marshall J. Glesby, Ira M. Jacobson. (2011) Randomized Trial Comparing Dose Reduction and Growth Factor Supplementation for Management of Hematological Side Effects in HIV/Hepatitis C Virus Patients Receiving Pegylated-Interferon and Ribavirin. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:3, 261-268
CrossRef11
Shruti H. Mehta, Geoffrey C. Buckle. (2011) Assessment of liver disease (noninvasive methods). Current Opinion in HIV and AIDS 6:6, 465-471
CrossRef12
Vicente Soriano, Luz Martin-Carbonero, Eugenia Vispo, Pablo Labarga, Pablo Barreiro. (2011) Infección por virus de la inmunodeficiencia humana y hepatitis víricas. Enfermedades Infecciosas y Microbiología Clínica 29:9, 691-701
CrossRef13
L.E. Taylor, A.K. DeLong, M.A. Maynard, S. Chapman, P. Gholam, J.T. Blackard, J. Rich, K.H. Mayer. (2011) Acute Hepatitis C Virus in an HIV Clinic: A Screening Strategy, Risk Factors, and Perception of Risk. AIDS Patient Care and STDs 25:10, 571-577
CrossRef14
Amy G. Shah, Paula G. Smith, Richard K. Sterling. (2011) Comparison of FIB-4 and APRI in HIV–HCV Coinfected Patients with Normal and Elevated ALT. Digestive Diseases and Sciences 56:10, 3038-3044
CrossRef15
Josep Mallolas Masferrer, María Martínez-Rebollar, Montserrat Laguno Centeno. (2011) Tratamiento de la hepatitis por virus C en pacientes coinfectados por el virus de la inmunodeficiencia humana. Gastroenterología y Hepatología 34:8, 558-567
CrossRef16
Nadeera Sidique, Anita Kohli, Bhavana Shivakumar, Stephen Migueles, G Mani Subramanian, Susanna Naggie, Michael A Polis, Henry Masur, Shyam Kottilil. (2011) HIV/HCV-Coinfected Natural Viral Suppressors Have Better Virologic Responses to PEG-IFN and Ribavirin Than ARV-Treated HIV/HCV Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:2, e38-e40
CrossRef17
Olga M Klibanov, Shannon H Williams, Lisa S Smith, Jacqueline L Olin, Stephen B Vickery. (2011) Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. Pharmacotherapy 31:10, 951-974
CrossRef18
N. Laufer, L. Abusamra, F. Bolcic, A. Gun, M.J. Rolón, H. Pérez, A. Krolewiecki, H. Salomón, J. Quarleri, P. Cahn. (2011) No reduction of HCV viral load in HIV patients co-infected with HCV genotype 1 during a 30days course of nitazoxanide monotherapy. Antiviral Research
CrossRef19
R. R. Razonable. (2011) Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus. Mayo Clinic Proceedings 86:10, 1009-1026
CrossRef20
Rositsa B. Dimova, Marianthi Markatou, Andrew H. Talal. (2011) Information methods for model selection in linear mixed effects models with application to HCV data. Computational Statistics & Data Analysis 55:9, 2677-2697
CrossRef21
Aarthi Chary, Mark Holodniy. (2011) Interferon combination therapy for HIV/hepatitis C virus coinfection. Immunotherapy 3:9, 1087-1102
CrossRef22
Karen Chan Osilla, Glenn Wagner, Jeffrey Garnett, Bonnie Ghosh-Dastidar, Mallory Witt, Laveeza Bhatti, Matthew Bidwell Goetz. (2011) Patient and Provider Characteristics Associated with the Decision of HIV Coinfected Patients to Start Hepatitis C Treatment. AIDS Patient Care and STDs 25:9, 533-538
CrossRef23
Klaus Klumpp, David B. Smith. 2011. Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection. , 287-304.
CrossRef24
L. Martín-Carbonero, P. Tuma, E. Vispo, J. Medrano, P. Labarga, J. González-Lahoz, P. Barreiro, V. Soriano. (2011) Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis. Journal of Viral Hepatitis 18:8, 542-548
CrossRef25
Deepak Joshi, John O'Grady, Chris Taylor, Nigel Heaton, Kosh Agarwal. (2011) Liver transplantation in human immunodeficiency virus-positive patients. Liver Transplantation 17:8, 881-890
CrossRef26
Mary Olson, Ira M. Jacobson. (2011) Role of the nurse practitioner in the management of patients with chronic hepatitis C. Journal of the American Academy of Nurse Practitioners 23:8, 410-420
CrossRef27
Marie-Louise C. Vachon, Douglas T. Dieterich. (2011) The HIV/HCV-Coinfected Patient and New Treatment Options. Clinics in Liver Disease 15:3, 585-596
CrossRef28
Jason Grebely, Gail V. Matthews, Margaret Hellard, David Shaw, Ingrid van Beek, Kathy Petoumenos, Maryam Alavi, Barbara Yeung, Paul S. Haber, Andrew R. Lloyd, John M. Kaldor, Gregory J. Dore. (2011) Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. Journal of Hepatology 55:1, 76-85
CrossRef29
B. P. Linas, B. Wang, M. Smurzynski, E. Losina, R. J. Bosch, B. R. Schackman, J. Rong, P. E. Sax, R. P. Walensky, J. Schouten, K. A. Freedberg. (2011) The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. Journal of Viral Hepatitis 18:7, 506-512
CrossRef30
Lynn E. Taylor, Sarah E. Bowman, Stacey Chapman, Nickolas Zaller, Michael D. Stein, Patricia A. Cioe, Michaela A. Maynard, Barbara Hedgis McGovern. (2011) Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. Drug and Alcohol Dependence 116:1-3, 233-237
CrossRef31
Patrick Ingiliz, Marc-Antoine Valantin, Paul Preziosi, Laetitia Finzi, Raluka Pais, Larysa Fedchuk, Stéphanie Dominguez, Christine Katlama, Thierry Poynard, Yves Benhamou. (2011) Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: A retrospective repeated liver biopsy analysis. Journal of Hepatology
CrossRef32
T. Reiberger, B. A. Payer, L. Kosi, P. M. Heil, A. Rieger, M. Peck-Radosavljevic, . (2011) Concomitant Highly Active Antiretroviral Therapy Leads to Smaller Decline and Faster Recovery of CD4+ Cell Counts During and After Pegylated Interferon Plus Ribavirin Therapy in HIV-Hepatitis C Virus Coinfected Patients. Journal of Infectious Diseases 203:12, 1802-1806
CrossRef33
Alison A Murphy, Eva Herrmann, Anu O Osinusi, Lynn Wu, William Sachau, Richard A Lempicki, Jun Yang, Tei L Chung, Brad J Wood, Bart L Haagmans, Shyam Kottilil, Michael A Polis. (2011) Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. AIDS 25:9, 1179-1187
CrossRef34
A. A. Butt, T. Umbleja, J. W. Andersen, R. T. Chung, K. E. Sherman, . (2011) The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Alimentary Pharmacology & Therapeutics 33:11, 1234-1244
CrossRef35
Kunihisa Tsukada, Yasuhiko Sugawara, Junichi Kaneko, Sumihito Tamura, Natsuo Tachikawa, Yuji Morisawa, Shu Okugawa, Yoshimi Kikuchi, Shinichi Oka, Satoshi Kimura, Yutaka Yatomi, Masatoshi Makuuchi, Norihiro Kokudo, Kazuhiko Koike. (2011) Living Donor Liver Transplantations in HIV- and Hepatitis C Virus-Coinfected Hemophiliacs: Experience in a Single Center. Transplantation 91:11, 1261-1264
CrossRef36
Hiroaki Hagihara, Kazuhiro Nouso, Yoshiyuki Kobayashi, Yoshiaki Iwasaki, Shinichiro Nakamura, Kenji Kuwaki, Junichi Toshimori, Hirokazu Miyatake, Hideki Ohnishi, Hidenori Shiraha, Kazuhide Yamamoto. (2011) Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. International Journal of Clinical Oncology 16:3, 210-220
CrossRef37
C. Vellozzi, K. Buchacz, R. Baker, P. R. Spradling, J. Richardson, A. Moorman, E. Tedaldi, M. Durham, J. Ward, J. T. Brooks, . (2011) Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007. Journal of Viral Hepatitis 18:5, 316-324
CrossRef38
E. Angeli, A. Mainini, P. Meraviglia, M. Schiavini, E. Ricci, R. Giorgi, G. Gubertini, G. Rizzardini. (2011) Eligibility and Feasibility of the Treatment of Chronic Hepatitis C in a Cohort of Italian HIV-Positive Patients at a Single HIV Reference Center. AIDS Patient Care and STDs 25:5, 295-301
CrossRef39
Marion G. Peters, Vincent Soriano. 2011. HIV and the Liver. , 438-451.
CrossRef40
Deepak Joshi, John O'Grady, Doug Dieterich, Brian Gazzard, Kosh Agarwal. (2011) Increasing burden of liver disease in patients with HIV infection. The Lancet 377:9772, 1198-1209
CrossRef41
Paulina Deming, Ian R McNicholl. (2011) Coinfection with Human Immunodeficiency Virus and Hepatitis C Virus: Challenges and Therapeutic Advances Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 31:4, 357-368
CrossRef42
N. Laufer, F. Bolcic, M.J. Rolón, A. Martinez, R. Reynoso, H. Pérez, H. Salomón, P. Cahn, J. Quarleri. (2011) HCV RNA decline in the first 24h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin. Antiviral Research 90:1, 92-97
CrossRef43
E. S. A. Araújo, H. Dahari, A. U. Neumann, N. de Paula Cavalheiro, C. E. Melo, E. S. de Melo, T. J. Layden, S. J. Cotler, A. A. Barone. (2011) Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients. Journal of Viral Hepatitis 18:4, e52-e60
CrossRef44
Poordad, Fred, McCone, Jonathan Jr., Bacon, Bruce R., Bruno, Savino, Manns, Michael P., Sulkowski, Mark S., Jacobson, Ira M., Reddy, K. Rajender, Goodman, Zachary D., Boparai, Navdeep, DiNubile, Mark J., Sniukiene, Vilma, Brass, Clifford A., Albrecht, Janice K., Bronowicki, Jean-Pierre, . (2011) Boceprevir for Untreated Chronic HCV Genotype 1 Infection. New England Journal of Medicine 364:13, 1195-1206
Full Text45
Jason Grebely, Gail V. Matthews, Gregory J. Dore. (2011) Treatment of acute HCV infection. Nature Reviews Gastroenterology & Hepatology
CrossRef46
S. H. Mehta, J. Astemborski, G. D. Kirk, S. A. Strathdee, K. E. Nelson, D. Vlahov, D. L. Thomas. (2011) Changes in Blood-borne Infection Risk Among Injection Drug Users. Journal of Infectious Diseases 203:5, 587-594
CrossRef47
Evaldo Stanislau Affonso de Araújo, Harel Dahari, Scott J Cotler, Thomas J Layden, Avidan U Neumann, Carlos Eduardo Melo, Antonio Alci Barone. (2011) Pharmacodynamics of PEG-IFN-α-2a and HCV Response as a Function of IL28B Polymorphism in HIV/HCV-Coinfected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 56:2, 95-99
CrossRef48
Jae Young Jang, Raymond T. Chung. (2011) Chronic Hepatitis C. Gut and Liver 5:2, 117
CrossRef49
Glenn Wagner, Karen Chan Osilla, Jeffrey Garnett, Bonnie Ghosh-Dastidar, Laveeza Bhatti, Matthew Bidwell Goetz, Mallory Witt. (2011) Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients. AIDS Research and Treatment 2011, 1-7
CrossRef50
Seiji Ishiguro, Manami Inoue, Yasuhito Tanaka, Masashi Mizokami, Motoki Iwasaki, Shoichiro Tsugane. (2011) Impact of viral load of hepatitis C on the incidence of hepatocellular carcinoma: A population-based cohort study (JPHC Study). Cancer Letters 300:2, 173-179
CrossRef51
Oluwaseun Falade-Nwulia, Chloe L. Thio. (2011) Liver disease, HIV and aging. Sexual Health 8:4, 512
CrossRef52
R. Parker, J. Dutrieux, S. Beq, B. Lemercier, S. Rozlan, V. Fabre-Mersseman, M. Rancez, C. Gommet, B. Assouline, I. Rance, A. Lim, M. Morre, R. Cheynier. (2010) Interleukin-7 treatment counteracts IFN- therapy-induced lymphopenia and stimulates SIV-specific cytotoxic T lymphocyte responses in SIV-infected rhesus macaques. Blood 116:25, 5589-5599
CrossRef53
Jennifer C. Price, Chloe L. Thio. (2010) Liver Disease in the HIV–Infected Individual. Clinical Gastroenterology and Hepatology 8:12, 1002-1012
CrossRef54
Kenneth E Sherman, Janet W Andersen, Adeel A Butt, Triin Umbleja, Beverly Alston, Margaret J Koziel, Marion G Peters, Mark Sulkowski, Zachary D Goodman, Raymond T Chung. (2010) Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients (SLAM-C). JAIDS Journal of Acquired Immune Deficiency Syndromes 55:5, 597-605
CrossRef55
Richard K. Sterling, Jacob A. Wegelin, Paula G. Smith, R. Todd Stravitz, Velimir A. Luketic, Michael Fuchs, Puneet Puri, Mitchell L. Shiffman, Melissa A. Contos, A. Scott Mills, Arun J. Sanyal. (2010) Similar Progression of Fibrosis Between HIV/HCV–Infected and HCV–Infected Patients: Analysis of Paired Liver Biopsy Samples. Clinical Gastroenterology and Hepatology 8:12, 1070-1076
CrossRef56
Lourdes Rafael-Valdivia, José M. Miró, Antoni Rimola. (2010) Trasplante hepático en pacientes con infección por VIH. Gastroenterología y Hepatología 33:9, 660-669
CrossRef57
Paul J. Pockros, Fayez M. Hamzeh, Paul Martin, Ellen Lentz, Xiaolei Zhou, Sugantha Govindarajan, Anna S. Lok. (2010) Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology 52:4, 1193-1200
CrossRef58
Debika Bhattacharya, T Umbleja, F Carrat, R T Chung, M G Peters, F Torriani, J Andersen, J S Currier. (2010) Women Experience Higher Rates of Adverse Events During Hepatitis C Virus Therapy in HIV Infection: A Meta-Analysis. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:2, 170-175
CrossRef59
Harel Dahari, Evaldo S. Affonso de Araujo, Bart L. Haagmans, Thomas J. Layden, Scott J. Cotler, Antonio A. Barone, Avidan U. Neumann. (2010) Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes. Journal of Hepatology 53:3, 460-467
CrossRef60
Esperance Schaefer, Raymond T. Chung. (2010) HIV and HCV Coinfection: Where Are We in 2010?. Current Hepatitis Reports 9:3, 155-160
CrossRef61
Patrice Cacoub, Philippe Halfon, Eric Rosenthal, François Bailly, Firouze Bani Sadr, Yves Benhamou, Stéphane Chevaliez, Jean Michel Pawlotsky, Lionel Piroth, Yazdan Yazdanpanah, Stanislas Pol. (2010) Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: Modifications in three consecutive large surveys between 2004 and 2009. Journal of Hepatology 53:2, 230-237
CrossRef62
Hank S. Wang, Steven-Huy B. Han. (2010) Management of Hepatitis B in Special Patient Populations. Clinics in Liver Disease 14:3, 505-520
CrossRef63
Anne Rachline, Pierre Palmer, François Simon, Jean-Michel Molina. (2010) Case report: Cure of chronic infection with hepatitis C virus after 6 weeks of peg-interferon and ribavirin in a patient co-infected with HIV. Journal of Medical Virology 82:7, 1150-1151
CrossRef64
Raffaella Rosso, Antonio Di Biagio, Malgorzata Mikulska, Elena Nicco, Claudia Bernardini, Claudio Viscoli. (2010) Safety and efficacy of pegylated interferon and ribavirin in adolescents with human immunodeficiency virus and hepatitis C virus acquired perinatally. Journal of Medical Virology 82:7, 1110-1114
CrossRef65
Manabu Abe, Corinne Klett, Eberhard Wieland, Sascha Gille, Olfert Landt. (2010) Simultaneous Quantification and Genotyping of Hepatitis C Virus RNA by a Two-Step Real-Time PCR Assay on the Lightcycler Instrument. Folia Medica 52:3, 21-30
CrossRef66
Panel de expertos de Gesida, Plan Nacional sobre el Sida. (2010) Documento de consenso del Grupo de Estudio de Sida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2010). Enfermedades Infecciosas y Microbiología Clínica 28:6, 362.e1-362.e91
CrossRef67
Astrid C. Frank, Xiaozhen Zhang, Antonios Katsounas, Jennifer P. Bharucha, Shyamasundaran Kottilil, Tomozumi Imamichi. (2010) Interleukin-27, an Anti-HIV-1 Cytokine, Inhibits Replication of Hepatitis C Virus. Journal of Interferon & Cytokine Research 30:6, 427-431
CrossRef68
Alexander Monto, Robert T Schooley, Jennifer C Lai, Mark S Sulkowski, Raymond T Chung, Jean-Michel Pawlotsky, John G McHutchison, Ira M Jacobson. (2010) Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop. The American Journal of Gastroenterology 105:5, 989-1004
CrossRef69
M. Sánchez-Conde, M. L. Montes-Ramírez, P. Miralles, J. M. Castro Alvarez, J. M. Bellón, M. Ramírez, J. R. Arribas, I. Gutiérrez, J. C. López, J. Cosín, E. Alvarez, J. González, J. Berenguer. (2010) Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. Journal of Viral Hepatitis 17:4, 280-286
CrossRef70
Andri Rauch, Zoltán Kutalik, Patrick Descombes, Tao Cai, Julia Di Iulio, Tobias Mueller, Murielle Bochud, Manuel Battegay, Enos Bernasconi, Jan Borovicka, Sara Colombo, Andreas Cerny, Jean–François Dufour, Hansjakob Furrer, Huldrych F. Günthard, Markus Heim, Bernard Hirschel, Raffaele Malinverni, Darius Moradpour, Beat Müllhaupt, Andrea Witteck, Jacques S. Beckmann, Thomas Berg, Sven Bergmann, Francesco Negro, Amalio Telenti, Pierre–Yves Bochud. (2010) Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology 138:4, 1338-1345.e7
CrossRef71
Eugenia Vispo, Pablo Labarga, Josep M. Guardiola, Pablo Barreiro, Celia Miralles, Rafael Rubio, Pilar Miralles, Koldo Aguirrebengoa, Joseba Portu, Judit Morello, Sonia Rodriguez-Novoa, Vincent Soriano. (2010) Preemptive Erythropoietin Plus High Ribavirin Doses to Increase Rapid Virological Responses in HIV Patients Treated for Chronic Hepatitis C. AIDS Research and Human Retroviruses 26:4, 419-424
CrossRef72
Eva Van den Eynde, Juan Manuel Tiraboschi, Cristina Tural, Ricard Solà, José Antonio Mira, Daniel Podzamczer, Antoni Jou, Nuria Cañete, Juan Antonio Pineda, Albert Pahissa, Manuel Crespo. (2010) Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients. AIDS 24:7, 975-982
CrossRef73
L. Milazzo, I. Caramma, C. Mazzali, M. Cesari, M. Olivetti, M. Galli, S. Antinori. (2010) Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. Journal of Antimicrobial Chemotherapy 65:4, 735-740
CrossRef74
Kenneth A. Harris, Julia H. Arnsten, Alain H. Litwin. (2010) Successful Integration of Hepatitis C Evaluation and Treatment Services With Methadone Maintenance. Journal of Addiction Medicine 4:1, 20-26
CrossRef75
S. Rashkin, S. Rouster, Z. D. Goodman, K. E. Sherman. (2010) T-helper cells and liver fibrosis in hepatitis C virus-monoinfected patients. Journal of Viral Hepatitis 17:3, 222-226
CrossRef76
Pablo Labarga, Eugenia Vispo, Pablo Barreiro, Sonia Rodríguez-Novoa, Javier Pinilla, Judit Morello, Luz Martín-Carbonero, Paula Tuma, José Medrano, Vincent Soriano. (2010) Rate and Predictors of Success in the Retreatment of Chronic Hepatitis C Virus in HIV/Hepatitis C Virus Coinfected Patients With Prior Nonresponse or Relapse. JAIDS Journal of Acquired Immune Deficiency Syndromes 53:3, 364-368
CrossRef77
Anu Osinusi, Joseph J Rasimas, Rachel Bishop, Michael Proschan, Mary McLaughlin, Alison Murphy, Karoll J Cortez, Michael A Polis, Henry Masur, Donald Rosenstein, Shyam Kottilil. (2010) HIV/Hepatitis C Virus-Coinfected Virologic Responders to Pegylated Interferon and Ribavirin Therapy More Frequently Incur Interferon-Related Adverse Events Than Nonresponders Do. JAIDS Journal of Acquired Immune Deficiency Syndromes 53:3, 357-363
CrossRef78
Michael J Fischer, Christina M Wyatt, Kirsha Gordon, Cynthia L Gibert, Sheldon T Brown, David Rimland, Maria C Rodriguez-Barradas, Amy C Justice, Chirag R Parikh. (2010) Hepatitis C and the Risk of Kidney Disease and Mortality in Veterans With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 53:2, 222-226
CrossRef79
Alfonso Iorio, Emanuela Marchesini, Tahany Awad, Lise Lotte Gluud, Alfonso Iorio. 2010. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. .
CrossRef80
A. Boyd, K. Lacombe, P. Miailhes, J. Gozlan, P. Bonnard, J.-M. Molina, C. Lascoux-Combe, L. Serfaty, E. Gault, M. Desvarieux, P.-M. Girard. (2010) Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. Journal of Viral Hepatitis 17:1, 65-76
CrossRef81
Chun-Hao Chen, Ming-Lung Yu. (2010) Evolution of Interferon-Based Therapy for Chronic Hepatitis C. Hepatitis Research and Treatment 2010, 1-12
CrossRef82
G Brook, J Main, M Nelson, S Bhagani, E Wilkins, C Leen, M Fisher, Y Gilleece, R Gilson, A Freedman, R Kulasegaram, K Agarwal, C Sabin, C Deacon-Adams, . (2010) British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Medicine 11:1, 1-30
CrossRef83
Nada Kuljic-Kapulica, Dragutin Jovanovic, Dejana Savic, Elizabeta Ristanovic, Darko Nozic, Radmila Rajic. (2010) Therapy of chronic hepatitis C: Virologic response monitoring. Vojnosanitetski pregled 67:11, 923-927
CrossRef84
Neumann U Avidan, Deborah Goldstein, Lynn Rozenberg, Mary McLaughlin, Peter Ferenci, Henry Masur, Maria Buti, Anthony S Fauci, Michael A Polis, Shyam Kottilil. (2009) Hepatitis C Viral Kinetics During Treatment With Peg IFN-alpha-2b in HIV/HCV Coinfected Patients as a Function of Baseline CD4+ T-Cell Counts. JAIDS Journal of Acquired Immune Deficiency Syndromes 52:4, 452-458
CrossRef85
Karen Chan Osilla, Gery Ryan, Laveeza Bhatti, Matthew Goetz, Mallory Witt, Glenn Wagner. (2009) Factors That Influence an HIV Coinfected Patient's Decision to Start Hepatitis C Treatment. AIDS Patient Care and STDs 23:12, 993-999
CrossRef86
M. E. MANCUSO, M. G. RUMI, A. AGHEMO, E. SANTAGOSTINO, M. PUOTI, A. COPPOLA, M. COLOMBO, P. M. MANNUCCI. (2009) Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy. Journal of Thrombosis and Haemostasis 7:12, 1997-2005
CrossRef87
H.-H. Thein, Q. Yi, E. J. Heathcote, M. D. Krahn. (2009) Prognosis of hepatitis C virus-infected Canadian post-transfusion compensation claimant cohort. Journal of Viral Hepatitis 16:11, 802-813
CrossRef88
John D. Scott, Anna Wald, Mari Kitahata, Elizabeth Krantz, Linda Drolette, Lawrence Corey, Chia C. Wang. (2009) Hepatitis C Virus Is Infrequently Evaluated and Treated in an Urban HIV Clinic Population. AIDS Patient Care and STDs 23:11, 925-929
CrossRef89
Lynn Rozenberg, Bart L Haagmans, Avidan U Neumann, Grace Chen, Mary McLaughlin, Rachel S Levy-Drummer, H Masur, Robin L Dewar, Peter Ferenci, Marcelo Silva, Maria S Viola, Michael A Polis, Shyam Kottilil. (2009) Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. AIDS 23:18, 2439-2450
CrossRef90
Jeffrey J. Weiss, Susan Morgello. (2009) Psychiatric management of HIV/HCV-coinfected patients beginning treatment for hepatitis C virus infection: survey of provider practices. General Hospital Psychiatry 31:6, 531-537
CrossRef91
Andri Rauch, Silvana Gaudieri, Chloe Thio, Pierre-Yves Bochud. (2009) Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 10:11, 1819-1837
CrossRef92
Aurélie Schnuriger, Stéphanie Dominguez, Marguerite Guiguet, Sawsan Harfouch, Assia Samri, Zineb Ouazene, Laurence Slama, Anne Simon, Marc-Antoine Valantin, Vincent Thibault, Brigitte Autran. (2009) Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS 23:16, 2079-2089
CrossRef93
Lise Lotte Gluud, Emanuela Marchesini, Alfonso Iorio. (2009) Peginterferon Plus Ribavirin for Chronic Hepatitis C in Patients With Human Immunodeficiency Virus. The American Journal of Gastroenterology 104:9, 2335-2341
CrossRef94
Glenn Wagner, Gery Ryan, Karen Chan Osilla, Laveeza Bhatti, Matthew Goetz, Mallory Witt. (2009) Treat Early or Wait and Monitor? A Qualitative Analysis of Provider Hepatitis C Virus Treatment Decision-Making in the Context of HIV Coinfection. AIDS Patient Care and STDs 23:9, 715-725
CrossRef95
James R. Burton, Gregory T. Everson. (2009) HCV NS5B Polymerase Inhibitors. Clinics in Liver Disease 13:3, 453-465
CrossRef96
Juan Berenguer, Julio Álvarez-Pellicer, Pilar Miralles Martín, José López-Aldeguer, Miguel Angel Von-Wichmann, Carmen Quereda, Josep Mallolas, José Sanz, Cristina Tural, José María Bellón, Juan González-García, . (2009) Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 50:2, 407-413
CrossRef97
Marie-Louise Vachon, Douglas T. Dieterich. (2009) HIV and coinfected patients. Current Hepatitis Reports 8:3, 103-110
CrossRef98
Adeel A. Butt, Joel Tsevat, Anthony C. Leonard, Obaid S. Shaikh, Deborah McMahon, Uzma A. Khan, Zachariah Dorey-Stein, Vincent Lo Re. (2009) Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. International Journal of Infectious Diseases 13:4, 449-455
CrossRef99
Alain H. Litwin, Kenneth A. Harris, Shadi Nahvi, Philippe J. Zamor, Irene J. Soloway, Peter L. Tenore, Daniel Kaswan, Marc. N. Gourevitch, Julia H. Arnsten. (2009) Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. Journal of Substance Abuse Treatment 37:1, 32-40
CrossRef100
L. Milazzo, L. Meroni, M. Galazzi, M. Cesari, I. Caramma, G. Marchetti, M. Galli, S. Antinori. (2009) Does fluvastatin favour HCV replication in vivo ? A pilot study on HIV-HCV coinfected patients. Journal of Viral Hepatitis 16:7, 479-484
CrossRef101
J. Berenguer, J. Gonzalez-Garcia, J. Lopez-Aldeguer, M. A. Von-Wichmann, C. Quereda, A. Hernando, J. Sanz, C. Tural, E. Ortega, J. Mallolas, I. Santos, P. Miralles, M. L. Montes, J. M. Bellon, H. Esteban, . (2009) Pegylated interferon 2a plus ribavirin versus pegylated interferon 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. Journal of Antimicrobial Chemotherapy 63:6, 1256-1263
CrossRef102
José F Pascual-Pareja, Alejandra Caminoa, Javier Larrauri, Juan González-García, Maria L Montes, Jesús Díez, Marta Grande, José R Arribas. (2009) HAART is associated with lower hepatic necroinflammatory activity in HIV–hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/μl at the time of liver biopsy. AIDS 23:8, 971-975
CrossRef103
Carmen Landaverde, Sammy Saab. (2009) Optimizing peginterferon and ribavirin administration in difficult-to-treat patient populations. Current Hepatitis Reports 8:2, 43-51
CrossRef104
Dominique Salmon-Ceron, Eric Rosenthal, Charlotte Lewden, Vincent Bouteloup, Thierry May, Christine Burty, Fabrice Bonnet, Dominique Costagliola, Eric Jougla, Caroline Semaille, Philippe Morlat, Patrice Cacoub, Geneviève Chêne. (2009) Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study. Journal of Hepatology 50:4, 736-745
CrossRef105
Marc G. Ghany, Doris B. Strader, David L. Thomas, Leonard B. Seeff. (2009) Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49:4, 1335-1374
CrossRef106
S. Moreno, J. García-Samaniego, A. Moreno, E. Ortega, J. A. Pineda, J. del Romero, C. Tural, M. A. von Wichmann, J. Berenguer, Á. Castro, R. Espacio. (2009) Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. Journal of Viral Hepatitis 16:4, 249-258
CrossRef107
Nicolás Merchante, Ignacio de los Santos-Gil, Dolores Merino, Mercedes González-Serrano, José A. Mira, Jesús Sanz-Sanz, Elisa Fernández-Fuertes, Josefa Ruiz-Morales, José del Valle, Juan Macías, Antonio Moro, Juan A. Pineda. (2009) Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. Journal of Hepatology 50:4, 684-692
CrossRef108
Kyung-Ah Kim, Wenyu Lin, Andrew W. Tai, Run-Xuan Shao, Ethan Weinberg, Carolina B. De Sa Borges, Atul K. Bhan, Hui Zheng, Yoshitaka Kamegaya, Raymond T. Chung. (2009) Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. Journal of Hepatology 50:4, 705-711
CrossRef109
J. T. DENHOLM, E. J. WRIGHT, A. STREET, J. J. SASADEUSZ. (2009) HCV treatment with pegylated interferon and ribavirin in patients with haemophilia and HIV/HCV co-infection. Haemophilia 15:2, 538-543
CrossRef110
Jama M. Darling, Michael W. Fried. (2009) Nitazoxanide: Beyond Parasites Toward a Novel Agent for Hepatitis C. Gastroenterology 136:3, 760-763
CrossRef111
B. de Felipe, M. Leal, N. Soriano-Sarabia, A. Gutiérrez, L. López-Cortés, S. Molina-Pinelo, A. Vallejo. (2009) HCV RNA in peripheral blood cell subsets in HCV-HIV coinfected patients at the end of PegIFN/RBV treatment is associated with virologic relapse. Journal of Viral Hepatitis 16:1, 21-27
CrossRef112
Eleni Nastouli, Emma C. Thomson, Peter Karayiannis, Janice Main, Myra McClure, David Muir. (2009) Diagnosing acute hepatitis C in HIV-infected patients: Nucleic acid testing compared with antibody and antigen–antibody detecting methods. Journal of Clinical Virology 44:1, 78-80
CrossRef113
Michiko Shindo. (2009) Treatment of chronic hepatitis C: present and future. Kanzo 50:7, 345-355
CrossRef114
Marie-Louise C Vachon, Nazia Qazi, Douglas T Dieterich. (2009) HCV treatment challenges in patients co-infected with HIV. HIV Therapy 3:1, 87-100
CrossRef115
Debbie Hartwell, Jonathan Shepherd. (2009) Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and meta-analysis. International Journal of Technology Assessment in Health Care 25:01, 56
CrossRef116
Montserrat Laguno, Carmen Cifuentes, Javier Murillas, Sergio Veloso, Maria Larrousse, Antoni Payeras, Lucia Bonet, Francese Vidal, Ana Milinkovic, Antoni Bassa, Concha Villalonga, Iñaki Pérez, Cristina Tural, Maria Martínez-Rebollar, Marta Calvo, Jose Luis Blanco, Estaban Martínez, Jose M. Sánchez-Tapias, Jose M. Gatell, Jose Mallolas. (2009) Randomized trial comparing pegylated interferon α-2b versus pegylated interferon α-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 49:1, 22-31
CrossRef117
Natasha Walzer, Steven L Flamm. (2009) Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations. Expert Review of Clinical Pharmacology 2:1, 67-76
CrossRef118
N. Terrault. (2008) Treatment of Hepatitis C in the HIV-Infected Subject. International Journal of Infectious Diseases 12, e19
CrossRef119
Lionel Piroth, Fabrice Carrat, Sylvie Larrat, Isabelle Goderel, Benoit Martha, Christopher Payan, Françoise Lunel-Fabiani, Firouze Bani-Sadr, Christian Perronne, Patrice Cacoub, Stanislas Pol, Patrice Morand. (2008) Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV–HCV co-infected patients on HCV therapy. Journal of Hepatology 49:6, 892-898
CrossRef120
S. Zhao, D. Cheng, E. Liu, H. Yu, H. Yang, X. Xue, Y. Chu. (2008) Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients. European Journal of Clinical Microbiology & Infectious Diseases 27:12, 1183-1192
CrossRef121
L. Martín-Carbonero, M. Puoti, J. García-Samaniego, A. De Luca, E. Losada, G. Quinzan, R. Bruno, A. Mariño, M. González, M. Núñez, V. Soriano. (2008) Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. Journal of Viral Hepatitis 15:10, 710-715
CrossRef122
Duncan Smith‐Rohrberg Maru, Robert Douglas Bruce, Sanjay Basu, Frederick L. Altice. (2008) Clinical Outcomes of Hepatitis C Treatment in a Prison Setting: Feasibility and Effectiveness for Challenging Treatment Populations. Clinical Infectious Diseases 47:7, 952-961
CrossRef123
Renee Pozza. (2008) Clinical management of HIV/hepatitis C virus coinfection. Journal of the American Academy of Nurse Practitioners 20:10, 496-505
CrossRef124
Barbara Roe, William W. Hall. (2008) Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus. Expert Reviews in Molecular Medicine 10,
CrossRef125
Silvio Garattini. (2008) Is there discrimination in access to therapy for HCV patients?. Journal of Hepatology 49:4, 491-493
CrossRef126
Mathieu Quesnel-Vallières, Mireille Lemay, Normand Lapointe, Steven R. Martin, Hugo Soudeyns. (2008) HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1. Journal of Clinical Virology 43:2, 236-240
CrossRef127
Annika Kau, Johannes Vermehren, Christoph Sarrazin. (2008) Treatment predictors of a sustained virologic response in hepatitis B and C. Journal of Hepatology 49:4, 634-651
CrossRef128
Teresa Santantonio, Johannes Wiegand, J. Tilman Gerlach. (2008) Acute hepatitis C: Current status and remaining challenges. Journal of Hepatology 49:4, 625-633
CrossRef129
Janet W. Andersen. 2008. AIDS Clinical Trials Group (ACTG). .
CrossRef130
J. A. Mira, L. F. Lopez-Cortes, P. Barreiro, C. Tural, M. Torres-Tortosa, I. de los Santos Gil, P. Martin-Rico, M. J. Rios-Villegas, J. J. Hernandez-Burruezo, D. Merino, M. A. Lopez-Ruz, A. Rivero, L. Munoz, M. Gonzalez-Serrano, A. Collado, J. Macias, P. Viciana, V. Soriano, J. A. Pineda. (2008) Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. Journal of Antimicrobial Chemotherapy 62:6, 1365-1373
CrossRef131
Florence Nicot, Florence Legrand-Abravanel, Thierry Lafont, Martine Dubois, Karine Sauné, Christophe Pasquier, Etienne Chatelut, Jacques Izopet. (2008) Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. Journal of Medical Virology 80:9, 1523-1529
CrossRef132
Jason P Smith. (2008) Treatment Options for Patients with Hepatitis C: Role of Pharmacists in Optimizing Treatment Response and Managing Adverse Events. Pharmacotherapy 28:9, 1151-1161
CrossRef133
Ingrid V. Bassett, Claire Farel, Emily D. Szmuilowicz, Rochelle P. Walensky. (2008) HIV/AIDS: AIDS Drug Assistance Programs in the Era of Routine HIV Testing. Clinical Infectious Diseases 47:5, 695-701
CrossRef134
Jag H. Khalsa, Glenn Treisman, Elinore McCance-Katz, Ellen Tedaldi. (2008) Medical Consequences of Drug Abuse and Co-Occurring Infections: Research at the National Institute on Drug Abuse. Substance Abuse 29:3, 5-16
CrossRef135
Paul J. Pockros, David Nelson, Eliot Godofsky, Maribel Rodriguez-Torres, Gregory T. Everson, Michael W. Fried, Reem Ghalib, Stephen Harrison, Lisa Nyberg, Mitchell L. Shiffman, Isabel Najera, Anna Chan, George Hill. (2008) R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 48:2, 385-397
CrossRef136
Marc-Arthur Loko, Laurent Castera, François Dabis, Brigitte Le Bail, Maria Winnock, Gaëlle Coureau, Paulette Bioulac-Sage, Victor de Ledinghen, Didier Neau, . (2008) Validation and Comparison of Simple Noninvasive Indexes for Predicting Liver Fibrosis in HIV-HCV-Coinfected Patients: ANRS CO3 Aquitaine Cohort. The American Journal of Gastroenterology 103:8, 1973-1980
CrossRef137
Philippe Halfon, Marc Bourlière, Hacène Khiri, Guillaume Pénaranda, Agnes Martineau, Valérie Oulès, Jérôme Courcambeck, Patrick Philibert. (2008) Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy. AIDS 22:13, 1694-1696
CrossRef138
Stuart K. Roberts, Graham Cooksley, Gregory J. Dore, Richard Robson, David Shaw, Heather Berns, George Hill, Klaus Klumpp, Isabel Najera, Carla Washington. (2008) Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 48:2, 398-406
CrossRef139
R. Chou, S. Carson, B. K. S. Chan. (2008) Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials. Journal of Viral Hepatitis 15:8, 551-570
CrossRef140
J. J. WEISS, L. BHATTI, D. T. DIETERICH, B. R. EDLIN, D. A. FISHBEIN, M. B. GOETZ, K. YU, G. J. WAGNER. (2008) Hepatitis C patients’ self-reported adherence to treatment with pegylated interferon and ribavirin. Alimentary Pharmacology & Therapeutics 28:3, 289-293
CrossRef141
Vincent Lo Re, Jay R. Kostman, Valerianna K. Amorosa. (2008) Management Complexities of HIV/Hepatitis C Virus Coinfection in the Twenty-First Century. Clinics in Liver Disease 12:3, 587-609
CrossRef142
Stanislas Pol, Vincent Soriano. (2008) Management of Chronic Hepatitis C Virus Infection in HIV‐Infected Patients. Clinical Infectious Diseases 47:1, 94-101
CrossRef143
Gail V Matthews, Gregory J Dore. (2008) HIV and hepatitis C coinfection. Journal of Gastroenterology and Hepatology 23:7pt1, 1000-1008
CrossRef144
D. O. Shea, H. Tuite, G. Farrell, M. Codd, F. Mulcahy, S. Norris, C. Bergin. (2008) Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals. Journal of Viral Hepatitis 15:7, 482-489
CrossRef145
Marina B. Klein, Curtis Cooper, Marie-Josée Brouillette, Nancy L. Sheehan, Chawki Benkelfat, Lawrence Annable, Francine Weston, Deborah Kraus, Joel Singer. (2008) CTN-194 (PICCO): Design of a trial of citalopram for the prevention of depression and its consequences in HIV-Hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Contemporary Clinical Trials 29:4, 617-630
CrossRef146
M. Crespo, J. A. Mira, J. A. Pineda, E. V. d. Eynde, M. J. Rios-Villegas, A. Collado, J. A. Giron-Gonzalez, L. F. Lopez-Cortes, M. Gonzalez-Serrano, A. Rivero, D. Merino, J. I. Esteban. (2008) Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. Journal of Antimicrobial Chemotherapy 62:4, 793-796
CrossRef147
Eliana Z. Agudelo, Norah A. Terrault. (2008) Optimizing therapy in treatment-naïve genotype 1 patients. Current Hepatitis Reports 7:2, 64-71
CrossRef148
Shruti H. Mehta, Becky L. Genberg, Jacquie Astemborski, Ravi Kavasery, Gregory D. Kirk, David Vlahov, Steffanie A. Strathdee, David L. Thomas. (2008) Limited Uptake of Hepatitis C Treatment Among Injection Drug Users. Journal of Community Health 33:3, 126-133
CrossRef149
David M. Novick, Mary Jeanne Kreek. (2008) Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction 103:6, 905-918
CrossRef150
David M Iser, Joseph J Sasadeusz. (2008) Current treatment of HIV/hepatitis B virus coinfection. Journal of Gastroenterology and Hepatology 23:5, 699-706
CrossRef151
José del Valle, José A Mira, Ignacio de los Santos, Luis F López-Cortés, Dolores Merino, Antonio Rivero, José A Girón, María J Ríos-Villegas, Mercedes González-Serrano, Antonio Collado, José A García-García, Juan A Pineda. (2008) Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients. AIDS 22:8, 923-930
CrossRef152
J. T. Blackard, K. E. Sherman. (2008) HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver?. Journal of Viral Hepatitis 15:5, 323-330
CrossRef153
Patrice Cacoub, Fabrice Carrat, Pierre Bédossa, Jérôme Lambert, Guillaume Pénaranda, Christian Perronne, Stanislas Pol, Philippe Halfon. (2008) Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study – ANRS HC02. Journal of Hepatology 48:5, 765-773
CrossRef154
Emma C. Thomson, Janice Main. (2008) Epidemiology of hepatitis C virus infection in HIV-infected individuals. Journal of Viral Hepatitis 0:0, 080423192604581-???
CrossRef155
Tracy Swan, Raymond T. Chung. (2008) Development of novel agents for the treatment of hepatitis C virus. Hepatology 47:4, 1426-1426
CrossRef156
Roberto J. Carvalho-Filho, Leonardo L. Schiavon, Janaína L. Narciso-Schiavon, Juliana P. Sampaio, Valéria P. Lanzoni, Maria Lucia G. Ferraz, Antonio Eduardo B. Silva. (2008) Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection. Liver International 28:4, 486-493
CrossRef157
Y. MAOR, J. M. SCHAPIRO, D. BASHARI, Y. LURIE, R. SAFADI, O. SEGOL, M. PARITSKY, Z. RACHLIS, B. AVIDAN, S. BAR-MEIR, U. MARTINOWITZ. (2008) Treatment of hepatitis C in patients with haemophilia – the Israeli National Hemophilia Center experience. Haemophilia 14:2, 336-342
CrossRef158
Alexander Monto, Sue Currie, Teresa L. Wright. (2008) Liver Disease in Injection Drug Users with Hepatitis C, With and Without HIV Coinfection. Journal of Addictive Diseases 27:2, 49-59
CrossRef159
Ellen M. Tedaldi. (2008) Emerging Therapies for Hepatitis C and HIV in Drug Abusers. Journal of Addictive Diseases 27:2, 83-91
CrossRef160
David L. Thomas. (2008) The Challenge of Hepatitis C in the HIV-Infected Person. Annual Review of Medicine 59:1, 473-485
CrossRef161
Mark S. Sulkowski. (2008) Viral hepatitis and HIV coinfection. Journal of Hepatology 48:2, 353-367
CrossRef162
J. Berenguer, J. M. Bellon, P. Miralles, E. Alvarez, I. Castillo, J. Cosin, J. C. Lopez, M. Sanchez Conde, B. Padilla, S. Resino. (2008) Association between Exposure to Nevirapine and Reduced Liver Fibrosis Progression in Patients with HIV and Hepatitis C Virus Coinfection. Clinical Infectious Diseases 46:1, 137-143
CrossRef163
Luz Martin-Carbonero, Marina Nuñez, Ana Mariño, Federico Alcocer, Llucía Bonet, Javier García-Samaniego, Pilar López-Serrano, Miguel Cordero, Joseba Portu, Vincent Soriano. (2008) Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 22:1, 15-21
CrossRef164
He-Jun Yuan, William M Lee. (2008) Nonresponse to Treatment for Hepatitis C. Drugs 68:1, 27-42
CrossRef165
Laure Valerio, Yazdan Yazdanpanah, Isabelle Poizot-Martin, Eric Rosenthal, Catherine Marimoutou, Jean-Albert Gastaut, Albert Tran, Pierre Dellamonica, Kenneth A Freedberg, Christian Pradier. (2008) Baseline CD4 Cell Count and Outcome of Pegylated Interferon Plus Ribavirin Therapy in HIV/Hepatitis C Virus-Coinfected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 47:1, 50-55
CrossRef166
Carrie Reed, Sherri O. Stuver, Sheila Tumilty, David Nunes, Jessica E. Murray, Camilla S. Graham, Margaret James Koziel, Donald E. Craven, Paul R. Skolnik, C. Robert Horsburgh. (2008) Predictors of Treatment for Hepatitis C Virus (HCV) Infection in Drug Users. Substance Abuse 29:1, 5-15
CrossRef167
Milos Opravil, Joe Sasadeusz, David A Cooper, Jürgen K Rockstroh, Nathan Clumeck, Bonaventura Clotet, Julio Montaner, Francesca J Torriani, Jean DePamphilis, Douglas T Dieterich. (2008) Effect of Baseline CD4 Cell Count on the Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Patients With HIV/Hepatitis C Virus Coinfection. JAIDS Journal of Acquired Immune Deficiency Syndromes 47:1, 36-49
CrossRef168
Marion Peters, Oren K. Fix. 2008. Hepatitis Virus Infections. , 415-423.
CrossRef169
Patrice Cacoub, Philippe Halfon, Eric Rosenthal, Gilles Pialoux, Yves Benhamou, Christian Perronne, Stanislas Pol. (2008) Treatment of hepatitis C virus in human immunodeficiency virus infected patients in “real life”: Modifications in two large surveys between 2004 and 2006. Journal of Hepatology 48:1, 35-42
CrossRef170
Nyingi Kemmer, Guy W. Neff. (2007) Managing chronic hepatitis C in the difficult-to-treat patient. Liver International 27:10, 1297-1310
CrossRef171
Kenneth E. Sherman, Russell Fleischer, Katherine Laessig, Jeffrey Murray, William Tauber, Debra Birnkrant. (2007) Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations. Hepatology 46:6, 2014-2020
CrossRef172
B. H. McGovern, C. Birch, M. T. Zaman, I. Bica, D. Stone, J. R. Quirk, B. Davis, K. Zachary, N. Basgoz, F. G. Cook, R. T. Gandhi. (2007) Managing Symptomatic Drug-Induced Liver Injury in HIV--Hepatitis C Virus--Coinfected Patients: A Role for Interferon. Clinical Infectious Diseases 45:10, 1386-1392
CrossRef173
Minhee Kang, Raymond T Chung. (2007) The Role of Early Viral Decline in the Treatment of Hepatitis C in HIV-1-Coinfected Persons. JAIDS Journal of Acquired Immune Deficiency Syndromes 46:3, 371-373
CrossRef174
Veronique Nussenblatt, Mary McLaughlin, Catherine A. Rehm, Richard A. Lempicki, Terry Brann, Jun Yang, Michael Proschan, Helene C. Highbarger, Robin L. Dewar, Tom Imamichi, Chad Koratich, Avidan U. Neumann, Henry Masur, Michael A. Polis, Shyam Kottilil. (2007) Immunodeficiency and Intrinsic IFN Resistance Are Associated with Viral Breakthrough to HCV Therapy in HIV-Coinfected Patients. AIDS Research and Human Retroviruses 23:11, 1354-1359
CrossRef175
Marija Zeremski, Andrew H Talal. (2007) Hepatitis C viral kinetics during treatment of hepatitis C virus/HIV coinfected patients. Current Opinion in HIV and AIDS 2:6, 489-495
CrossRef176
S. Chevaliez, J.-M. Pawlotsky. (2007) Practical use of hepatitis C virus kinetics monitoring in the treatment of chronic hepatitis C. Journal of Viral Hepatitis 14:s1, 77-81
CrossRef177
Mark S Sulkowski, Shruti H Mehta, Michael S Torbenson, Yvonne Higgins, Sherilyn C Brinkley, Ruben Montes de Oca, Richard D Moore, Nezam H Afdhal, David L Thomas. (2007) Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 21:16, 2209-2216
CrossRef178
Rohit Satoskar, Donald M Jensen. (2007) Retreatment of chronic hepatitis C in previous non-responders and relapsers. Expert Opinion on Pharmacotherapy 8:15, 2491-2503
CrossRef179
D. KEVANS, G. FARRELL, S. HOPKINS, N. MAHMUD, B. WHITE, S. NORRIS, C. BERGIN. (2007) Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes. Haemophilia 13:5, 593-598
CrossRef180
Piero Luigi Almasio, Claudia Cottone, Francesca D'Angelo. (2007) Pegylated interferon therapy in chronic hepatitis C: lights and shadows of an innovative treatment. Digestive and Liver Disease 39, S88-S95
CrossRef181
AU Neumann, MA Polis, L Rozenberg, JO Jackson, KN Reitano, M McLaughlin, C Koratich, RL Dewar, H Masur, BL Haagmans, Shyam Kottilil. (2007) Differential antiviral effect of PEG-interferon-??-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS 21:14, 1855-1865
CrossRef182
J. Berenguer, J. M. Bellón, P. Miralles, E. Álvarez, M. Sánchez-Conde, J. Cosín, J. C. López, F. Álvarez, P. Catalán, S. Resino. (2007) Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. Journal of Viral Hepatitis 0:0, 070901052026008-???
CrossRef183
Roberto J. Firpi, David R. Nelson. (2007) Current and Future Hepatitis C Therapies. Archives of Medical Research 38:6, 678-690
CrossRef184
Marina N????ez, Angel Mari??o, Celia Miralles, Miguel A Berd??n, Julio Sola, Juan Jose Hernandez-Burruezo, Maria Jose Galindo, Pablo Barreiro, Luz Martin-Carbonero, Vincent Soriano. (2007) Baseline Serum Hepatitis C Virus (HCV) RNA Level and Response at Week 4 Are the Best Predictors of Relapse After Treatment With Pegylated Interferon Plus Ribavirin in HIV/HCV-Coinfected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:4, 439-444
CrossRef185
Tomasz Laskus, Jeffrey Wilkinson, Roksana Karim, Wendy Mack, Marek Radkowski, Marina deGiacomo, Jonathan Nasseri, Zhi Chen, Jiaao Xu, Andrea Kovacs. (2007) Hepatitis C virus quasispecies in HIV-infected women: Role of injecting drug use and highly active antiretroviral therapy (HAART). Hepatology 46:2, 359-370
CrossRef186
Marina Núñez, Celia Miralles, Miguel Angel Berdún, Elena Losada, Koldo Aguirrebengoa, Antonio Ocampo, Piedad Arazo, Manuel Cervantes, Ignacio de los Santos, Isabel San Joaquín, Santiago Echeverría, María José Galindo, Victor Asensi, Pablo Barreiro, Julio Sola, Juan José Hernandez-Burruezo, Josep Maria Guardiola, Miriam Romero, Javier García-Samaniego, Vincent Soriano, . (2007) Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial. AIDS Research and Human Retroviruses 23:8, 972-982
CrossRef187
Hussien Elsiesy, Douglas Dieterich. (2007) Viral hepatitis in patients with HIV infection. Current Hepatitis Reports 6:3, 103-113
CrossRef188
Harel Dahari, Marianthi Markatou, Marija Zeremski, Ivan Haller, Ruy M. Ribeiro, Teresa Licholai, Alan S. Perelson, Andrew H. Talal. (2007) Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. Journal of Hepatology 47:1, 23-30
CrossRef189
Claude Souvignet, Marianne Maynard, Marie-Claude Gagnieu, Christian Trepo. (2007) Ribavirin in combination therapy for HCV chronic infection in HIV patients: How to win the war after winning the first battle?. Journal of Hepatology 47:1, 1-3
CrossRef190
Nick Walsh, Peter Higgs, Nick Crofts. (2007) Recognition of Hepatitis C Virus Coinfection in HIV-Positive Injecting Drug Users in Asia. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:3, 363-365
CrossRef191
FT Aweeka, M Kang, J-Y Yu, P Lizak, B Alston, RT Chung, . (2007) Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team. HIV Medicine 8:5, 288-294
CrossRef192
Barbara H McGovern. (2007) Hepatitis C in the HIV-Infected Patient. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:Supplement 2, S47-S56
CrossRef193
Gregory J Dore, Francesca J Torriani, Maribel Rodriguez-Torres, Norber Br??u, Mark Sulkowski, Ricard Sola Lamoglia, Cristina Tural, Nathan Clumeck, Mark R Nelson, Maria C Mendes-Correa, Eliot W Godofsky, Douglas T Dieterich, Ellen Yetzer, Eduardo Lissen, David A Cooper. (2007) Baseline factors prognostic of sustained virological response in patients with HIV???hepatitis C virus co-infection. AIDS 21:12, 1555-1559
CrossRef194
AI Kim, A Dorn, R Bouajram, S Saab. (2007) The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis. HIV Medicine 8:5, 312-321
CrossRef195
Rui Sarmento-Castro, Ana Horta, Olga Vasconcelos, Helena Coelho, Josefina Mendez, Ana Paula Tavares, João Seabra, Manuela Duarte, Leonor Chaves, Olga Fortes, Cristina Recalde, Ângela Ventura, Nuno Pires, Luciana Pinho, Nancy Dias, Fátima Carneiro. (2007) Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV–HIV co-infection. Journal of Infection 54:6, 609-616
CrossRef196
M. S. Sulkowski, Y. Benhamou. (2007) Therapeutic issues in HIV/HCV-coinfected patients. Journal of Viral Hepatitis 14:6, 371-386
CrossRef197
Kenneth E. Sherman, Marion Peters, Margaret James Koziel. (2007) HIV and liver disease forum: Conference proceedings. Hepatology 45:6, 1566-1577
CrossRef198
Judith I. Tsui, David R. Bangsberg, Kathleen Ragland, Christopher S. Hall, Elise D. Riley. (2007) The Impact of Chronic Hepatitis C on Health-Related Quality of Life in Homeless and Marginally Housed Individuals with HIV. AIDS and Behavior 11:4, 603-610
CrossRef199
C. M. Behler, E. Vittinghoff, F. Lin, R. T. Chung, M. G. Peters, G. K. Robbins, P. A. Volberding. (2007) Hematologic Toxicity Associated with Interferon-Based Hepatitis C Therapy in HIV Type 1-Coinfected Subjects. Clinical Infectious Diseases 44:10, 1375-1383
CrossRef200
Debbie M. Cheng, David Nunes, Howard Libman, John Vidaver, Julie K. Alperen, Richard Saitz, Jeffrey H. Samet. (2007) Impact of Hepatitis C on HIV Progression in Adults With Alcohol Problems. Alcoholism: Clinical and Experimental Research 31:5, 829-836
CrossRef201
Margaret C. Shuhart. (2007) Hepatitis C and HIV coinfection. Current Hepatitis Reports 6:2, 46-53
CrossRef202
Adeel A. Butt, Joel Tsevat, Jawad Ahmad, A Obaid Shakil, Joseph M. Mrus. (2007) Biochemical and Virologic Parameters in Patients Co-Infected with Hepatitis C and HIV Versus Patients with Hepatitis C Mono-Infection. The American Journal of the Medical Sciences 333:5, 271-275
CrossRef203
Vincent Soriano, Massimo Puoti, Mark Sulkowski, Antonietta Cargnel, Yves Benhamou, Marion Peters, Stefan Mauss, Norbert Bräu, Angelos Hatzakis, Stanislas Pol, Juergen Rockstroh. (2007) Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel. AIDS 21:9, 1073-1089
CrossRef204
A. A. Butt, M. Skanderson, K. A. McGinnis, T. Ahuja, C. L. Bryce, A. E. Barnato, C.-C. H. Chang. (2007) Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis. Journal of Viral Hepatitis 0:0, 070507054112003-???
CrossRef205
C. Tural, R. Solà, R. Rubio, M. Santín, R. Planas, C. Quereda, J. Berenguer, M. Montes-Ramírez, B. Clotet, . (2007) Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study. Journal of Viral Hepatitis 0:0, 070502203756001-???
CrossRef206
Koziel, Margaret James, Peters, Marion G., . (2007) Viral Hepatitis in HIV Infection. New England Journal of Medicine 356:14, 1445-1454
Full Text207
N. J. Shire, J. A. Welge, K. E. Sherman. (2007) Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. Journal of Viral Hepatitis 14:4, 239-248
CrossRef208
Jason T. Blackard, Minhee Kang, J. Benjamin St. Clair, Wenyu Lin, Yoshitaka Kamegaya, Kenneth E. Sherman, Margaret James Koziel, Marion G. Peters, Janet Andersen, Raymond T. Chung. (2007) Viral Factors Associated with Cytokine Expression During HCV/HIV Co-Infection. Journal of Interferon & Cytokine Research 27:4, 263-270
CrossRef209
M. Bourlière, H. Fontaine, Y. Yazdanpanah, L. Piroth, Y. Benhamou. (2007) Co-infection avec les hépatites virales. Journal Africain d’Hépato-Gastroentérologie 1:1, 38-50
CrossRef210
John G. McHutchison, Michael P. Manns, Robert S. Brown, K. Rajender Reddy, Mitchell L. Shiffman, John B. Wong. (2007) Strategies for Managing Anemia in Hepatitis C Patients Undergoing Antiviral Therapy. The American Journal of Gastroenterology 102:4, 880-889
CrossRef211
M. Crespo, S. Sauleda, J. I. Esteban, A. Juarez, E. Ribera, A. L. Andreu, V. Falco, J. Quer, I. Ocaña, I. Ruiz, M. Buti, A. Pahissa, R. Esteban, J. Guardia. (2007) Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. Journal of Viral Hepatitis 14:4, 228-238
CrossRef212
Stephen D Shafran. (2007) Early Initiation of Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 44:5, 551-556
CrossRef213
Gary L. Davis, Kris Krawczynski, Gyongyi Szabo. (2007) Hepatitis C Virus Infection—Pathobiology and Implications for New Therapeutic Options. Digestive Diseases and Sciences 52:4, 857-875
CrossRef214
E. Rosenthal, G. Pialoux, N. Bernard, C. Pradier, D. Rey, M. Bentata, C. Michelet, S. Pol, C. Perronne, P. Cacoub, . (2007) Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). Journal of Viral Hepatitis 14:3, 183-188
CrossRef215
Jaydeep S. Kadam, Andrew H. Talal. (2007) Changing Treatment Paradigms: Hepatitis C Virus in HIV-Infected Patients. AIDS Patient Care and STDs 21:3, 154-168
CrossRef216
V.J. Moreno Cuerda, M. Morales Conejo, R. Rubio. (2007) Réplica. Revista Clínica Española 207:3, 151
CrossRef217
Marija Zeremski, Marianthi Markatou, Queenie B Brown, Gary Dorante, Susanna Cunningham-Rundles, Andrew H Talal. (2007) Interferon ?????Inducible Protein 10. JAIDS Journal of Acquired Immune Deficiency Syndromes PAP,
CrossRef218
Jenny O. Smith, Richard K. Sterling. (2007) Hepatitis C and HIV. Current Gastroenterology Reports 9:1, 83-90
CrossRef219
Nicole G. Campos, Joshua A. Salomon, Julie C. Servoss, David P. Nunes, Jeffrey H. Samet, Kenneth A. Freedberg, Sue J. Goldie. (2007) Cost-effectiveness of Treatment for Hepatitis C in an Urban Cohort Co-infected with HIV. The American Journal of Medicine 120:3, 272-279
CrossRef220
Vincent Lo Re, Jay R Kostman, Robert Gross, K Rajender Reddy, Karam Mounzer, Babette S Zemel, Hanna Rennert, Donald D Stieritz, Mary Putt, Ian Frank, Brian L Strom. (2007) Incidence and Risk Factors for Weight Loss During Dual HIV/Hepatitis C Virus Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 44:3, 344-350
CrossRef221
R. K. STERLING, C. D. LYONS, R. T. STRAVITZ, V. A. LUKETIC, A. J. SANYAL, M. E. CARR, T. J. SMITH, M. H. HACKNEY, M. J. CONTOS, S. A. MILLS, J. G. KUHN, M. E. NOLTE, M. L. SHIFFMAN. (2007) Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease. Haemophilia 13:2, 164-171
CrossRef222
Manuel Crespo, Juan I Esteban, Esteban Ribera, Vicenç Falco, Silvia Sauleda, María Buti, Rafael Esteban, Jaime Guardia, Inma Ocaña, Albert Pahissa. (2007) Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients. AIDS 21:4, 477-481
CrossRef223
Graham S Cooke, Janice Main. (2007) Improving the treatment of hepatitis C infection in the UK. Expert Opinion on Pharmacotherapy 8:2, 183-191
CrossRef224
Montserrat Laguno, Mar??a Larrousse, Javier Murillas, Jos?? Luis Blanco, Agathe Le??n, Ana Milinkovic, Montserrat Lonc??, Esteban Martinez, Jos?? Maria S??nchez-Tapias, Elisa de Lazzari, Josep Ma Gatell, Josep Costa, Josep Mallolas. (2007) Predictive Value of Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients Treated With an Interferon-Based Regimen Plus Ribavirin. JAIDS Journal of Acquired Immune Deficiency Syndromes 44:2, 174-178
CrossRef225
Kenneth E Sherman. (2007) New paradigms in the management of hepatitis C virus co-infections. Nature Clinical Practice Gastroenterology & Hepatology 4, S10-S16
CrossRef226
Helen M. Chun, Michael L. Landrum. (2007) Liver-Related Complications in HIV-Infected Individuals. Infectious Diseases in Clinical Practice 15:1, 38-48
CrossRef227
Leonardo L. Schiavon, Roberto J. Carvalho Filho, Janaína L. Narciso, Juliana P. Sampaio, Valéria P. Lanzoni, Maria Lucia G. Ferraz, Antonio Eduardo B. Silva. (2007) Expanding the applicability of noninvasive fibrosis markers in HIV/HCV co-infected patients. Hepatology 45:1, 257-258
CrossRef228
Andrew J. Muir, John G. McHutchison. (2006) Growth factors during HCV therapy may be “cost-effective”, but are they “effective”?. Hepatology 44:6, 1400-1403
CrossRef229
Anita Palepu, Debbie M. Cheng, Theresa Kim, David Nunes, John Vidaver, Julie Alperen, Richard Saitz, Jeffrey H. Samet. (2006) Substance abuse treatment and receipt of liver specialty care among persons coinfected with HIV/HCV who have alcohol problems. Journal of Substance Abuse Treatment 31:4, 411-417
CrossRef230
L. I. Backus, D. B. Boothroyd, B. R. Phillips, L. A. Mole. (2006) Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus. Journal of Viral Hepatitis 13:12, 799-810
CrossRef231
Jeffrey J. Weiss, Jack M. Gorman. (2006) Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV. Current HIV/AIDS Reports 3:4, 176-181
CrossRef232
Heinz Zoller, Wolfgang Vogel. (2006) Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV ? focus on pegylated interferon-alpha. International Journal of Nanomedicine 1:4, 399-409
CrossRef233
Lynne Wu, Shyam Kottilil, Richard Lempicki, Jun Yang, Mary McLaughlin, Zonghui Hu, Chad Koratich, Kristin N. Reitano, Catherine A. Rehm, Henry Masur, Brad Wood, David E. Kleiner, Michael A. Polis. (2006) Hepatic Histologic Response (HR) to Combination Therapy among HCV/HIV-Coinfected Individuals: Interferon Induces HR Independent of Sustained Virologic Response (SVR). AIDS Research and Human Retroviruses 22:11, 1091-1098
CrossRef234
Shruti H Mehta, Gregory M Lucas, Lisa B Mirel, Michael Torbenson, Yvonne Higgins, Richard D Moore, David L Thomas, Mark S Sulkowski. (2006) Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 20:18, 2361-2369
CrossRef235
Norah J. Shire, Paul S. Horn, Susan D. Rouster, Sandra Stanford, M. Elaine Eyster, Kenneth E. Sherman, . (2006) HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. Hepatology 44:5, 1146-1157
CrossRef236
Vincent Soriano, Pablo Labarga, Andrés Ruiz-Sancho, Javier Garcia-Samaniego, Pablo Barreiro. (2006) Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin. AIDS 20:17, 2225-2227
CrossRef237
Eduardo Lissen, Nathan Clumeck, Ricardo Sola, Maria Mendes-Correa, Julio Montaner, Mark Nelson, Jean DePamphilis, Mário Pessôa, Peter Buggisch, Janice Main, Douglas Dieterich. (2006) Histological response to pegIFNα-2a (40KD) plus ribavirin in HIV–hepatitis C virus co-infection. AIDS 20:17, 2175-2181
CrossRef238
Pablo Saiz de la Hoya-Zamácola, Andrés Marco-Mouriño, Gerardo Clemente-Ricote, Joaquín Portilla-Sogorb, Vicente Boix-Martínez, Óscar Núñez-Martínez, Sergio Reus-Bañuls, Nuria Teixidó i Pérez. (2006) Recomendaciones de expertos sobre el diagnóstico y tratamiento de la hepatitis C crónica en el medio penitenciario. Gastroenterología y Hepatología 29:9, 551-559
CrossRef239
Sergey Akimov, Oluwatoyin M Adeyemi. (2006) Peginterferon-α 2a in the treatment of chronic hepatitis C. Future Virology 1:6, 689-701
CrossRef240
Pablo Saiz De La Hoya-Zamácola, Andrés Marco-Mouriño, Gerardo Clemente-Ricote, Joaquín Portilla-Sogorb, Vicente Boix-Martínez, Óscar Núñez-Martínez, Sergio Reus-Bañuls, Nuria Teixidó i Pérez. (2006) Recomendaciones de expertos sobre el diagnóstico y tratamiento de la hepatitis C crónica en el medio penitenciario. Enfermedades Infecciosas y Microbiología Clínica 24:9, 568-575
CrossRef241
Jason T. Blackard, Minhee Kang, Kenneth E. Sherman, Margaret James Koziel, Marion G. Peters, Raymond T. Chung. (2006) Effects of HCV Treatment on Cytokine Expression During HCV/HIV Coinfection. Journal of Interferon & Cytokine Research 26:11, 834-838
CrossRef242
Armando Sánchez-Quijano, Eduardo Lissen-Otero. (2006) Tratamiento de las hepatitis víricas (II). Tratamiento de la hepatitis crónica C. Enfermedades Infecciosas y Microbiología Clínica 24:8, 518-526
CrossRef243
Cristina Tural i Llàcher. (2006) Aplicabilidad de la cinética del virus de la hepatitis C en el paciente coinfectado por el virus de la inmunodeficiencia humana. Medicina Clínica 127:15, 574-575
CrossRef244
Matthew L Cowan, James D Maxwell. (2006) Treatment of hepatitis C virus infection in intravenous drug users. Acta Neuropsychiatrica 18:5, 183-192
CrossRef245
M LAGUNO. (2006) Tratamiento de la hepatitis crónica C en el paciente coinfectado por el VIH. Gastroenterología y Hepatología 29, 154-157
CrossRef246
Kevin M. Comar, Richard K. Sterling. (2006) Coinfection with hepatitis C virus and HIV: The challenges of management. Current Hepatitis Reports 5:4, 154-161
CrossRef247
Andrew R. Lai, Karen T. Tashima, Lynn E. Taylor. (2006) Antiretroviral Medication Considerations for Individuals Coinfected with HIV and Hepatitis C Virus. AIDS Patient Care and STDs 20:10, 678-692
CrossRef248
Pierluigi Toniutto, Carlo Fabris, Mario Pirisi. (2006) Antiviral treatment of hepatitis C. Expert Opinion on Pharmacotherapy 7:15, 2025-2035
CrossRef249
D. Alvarez, D. T. Dieterich, N. Brau, L. Moorehead, L. Ball, M. S. Sulkowski. (2006) Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. Journal of Viral Hepatitis 13:10, 683-689
CrossRef250
P. Cacoub, E. Rosenthal, P. Halfon, D. Sene, C. Perronne, S. Pol. (2006) Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. Journal of Viral Hepatitis 13:10, 678-682
CrossRef251
Helen S. Yee, Sue L. Currie, Jama M. Darling, Teresa L. Wright. (2006) Management and Treatment of Hepatitis C Viral Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. The American Journal of Gastroenterology 101:10, 2360-2378
CrossRef252
Stéphane Chevaliez, Jean-Michel Pawlotsky. (2006) Clinical virology of hepatitis C virus. Future Virology 1:5, 649-657
CrossRef253
Jenny O. Smith, Richard K. Sterling. (2006) Hiv coinfection with hepatitis C and hepatitis B. Current Infectious Disease Reports 8:5, 409-418
CrossRef254
Hendrik Streeck, Jürgen K Rockstroh. (2006) Challenges in the treatment of HIV and HCV coinfection. Expert Review of Clinical Immunology 2:5, 811-822
CrossRef255
Frank J. Palella, Rose K. Baker, Anne C. Moorman, Joan S. Chmiel, Kathleen C. Wood, John T. Brooks, Scott D. Holmberg. (2006) Mortality in the Highly Active Antiretroviral Therapy Era. JAIDS Journal of Acquired Immune Deficiency Syndromes 43:1, 27-34
CrossRef256
Alice K Pau, Mary M. McLaughlin, Zonghui Hu, Amma F. Agyemang, Michael A. Polis, Shyam Kottilil. (2006) Predictors for Hematopoietic Growth Factors Use in HIV/HCV-Coinfected Patients Treated with Peginterferon Alfa 2b and Ribavirin. AIDS Patient Care and STDs 20:9, 612-619
CrossRef257
John Hornberger, Francesca J. Torriani, Douglas T. Dieterich, Norbert Bräu, Mark S. Sulkowski, Maribel Rodriguez Torres, Jesse Green, Kavita Patel. (2006) Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. Journal of Clinical Virology 36:4, 283-291
CrossRef258
A. A. BUTT, A. C. JUSTICE, M. SKANDERSON, C. GOOD, C. K. KWOH. (2006) Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Alimentary Pharmacology & Therapeutics 24:4, 585-591
CrossRef259
A. Moreno, R. Barcena, S. Garcia-Garzon, L. Moreno, C. Quereda, A. Muriel, J. Zamora, M. L. Mateos, M. J. Perez-Elias, A. Antela, S. Diz, A. Moreno, S. Moreno. (2006) Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus*. Journal of Viral Hepatitis 13:7, 466-473
CrossRef260
Esther Voigt, Christian Schulz, Gerd Klausen, Joerg Goelz, Stefan Mauss, Guenther Schmutz, Heiko Jessen, Lutwin Weitner, Antonius Mutz, Dietmar Schranz, Juergen K. Rockstroh, for the KAAD study group. (2006) Pegylated interferon α-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. Journal of Infection 53:1, 36-42
CrossRef261
Homayon Sidiq, Victor Ankoma-Sey. (2006) HIV-Related Liver Disease: Infections Versus Drugs. Gastroenterology Clinics of North America 35:2, 487-505
CrossRef262
Rise Stribling, Norman Sussman, John M. Vierling. (2006) Treatment of Hepatitis C Infection. Gastroenterology Clinics of North America 35:2, 463-486
CrossRef263
Richard K. Sterling, Eduardo Lissen, Nathan Clumeck, Ricard Sola, Mendes Cassia Correa, Julio Montaner, Mark S. Sulkowski, Francesca J. Torriani, Doug T. Dieterich, David L. Thomas, Diethelm Messinger, Mark Nelson, . (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43:6, 1317-1325
CrossRef264
S Hopkins, J Lambourne, G Farrell, L McCullagh, M Hennessy, S Clarke, F Mulcahy, C Bergin. (2006) Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals*. HIV Medicine 7:4, 248-254
CrossRef265
Andrew H. Talal, Ruy M. Ribeiro, Kimberly A. Powers, Michael Grace, Constance Cullen, Musaddeq Hussain, Marianthi Markatou, Alan S. Perelson. (2006) Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 43:5, 943-953
CrossRef266
Stéphanie Dominguez, Jade Ghosn, Marc-Antoine Valantin, Aurélie Schruniger, Anne Simon, Philippe Bonnard, Eric Caumes, Gilles Pialoux, Yves Benhamou, Vincent Thibault, Christine Katlama. (2006) Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 20:8, 1157-1161
CrossRef267
Andrés Ruiz-Sancho, Vicente Soriano. (2006) Coinfección por el VIH y el virus de la hepatitis C. Enfermedades Infecciosas y Microbiología Clínica 24:5, 335-346
CrossRef268
Nathan A. Merriman, Steven B. Porter, Colleen M. Brensinger, K. Rajender Reddy, Kyong-Mi Chang. (2006) Racial Difference in Mortality Among U.S. Veterans with HCV/HIV Coinfection. The American Journal of Gastroenterology 101:4, 760-767
CrossRef269
A. Moghaddam, N. Reinton, O. Dalgard. (2006) A rapid real-time PCR assay for determination of hepatitis C virus genotypes 1, 2 and 3a. Journal of Viral Hepatitis 13:4, 222-229
CrossRef270
Dawn A. Fishbein, Yungtai Lo, Dale Netski, David L. Thomas, Robert S. Klein. (2006) Predictors of Hepatitis C Virus RNA Levels in a Prospective Cohort Study of Drug Users. JAIDS Journal of Acquired Immune Deficiency Syndromes 41:4, 471-476
CrossRef271
Ruth Larson, Bernadette Capili, Margaret Eckert-Norton, Joseph P. Colagreco, Joyce K. Anastasi. (2006) Disorders of glucose metabolism in the context of human immunodeficiency virus infection. Journal of the American Academy of Nurse Practitioners 18:3, 92-103
CrossRef272
Debika Bhattacharya, Joanne C. Imperial, Emmet B. Keeffe. (2006) Chronic Hepatitis C in the Human Immunodeficiency Virus–Infected Patient: Management Strategies. Clinical Gastroenterology and Hepatology 4:3, 288-292
CrossRef273
Kirsty England, Claire Thorne, Marie-Louise Newell. (2006) Vertically acquired paediatric coinfection with HIV and hepatitis C virus. The Lancet Infectious Diseases 6:2, 83-90
CrossRef274
Camilla S Graham, Annalee Wells, Tun Liu, Kenneth E Sherman, Marion Peters, Raymond T Chung, Atul K Bhan, Janet Andersen, Margaret James Koziel. (2006) Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. AIDS 20:3, 345-351
CrossRef275
Jürgen K Rockstroh. (2006) Management of hepatitis C/HIV coinfection. Current Opinion in Infectious Diseases 19:1, 8-13
CrossRef276
Jason T. Blackard, Florence Komurian-Pradel, Magali Perret, Mireille Sodoyer, Laura Smeaton, J. Benjamin St. Clair, Stacey Chapman, Lynn E. Taylor, Glaucia Paranhos-Baccalà, Raymond T. Chung. (2006) Intrahepatic cytokine expression is downregulated during HCV/HIV co-infection. Journal of Medical Virology 78:2, 202-207
CrossRef277
Jean-Michel Pawlotsky. (2006) Therapy of hepatitis C: From empiricism to eradication. Hepatology 43:S1, S207-S220
CrossRef278
David L. Thomas. (2006) Growing importance of liver disease in HIV-infected persons. Hepatology 43:S1, S221-S229
CrossRef279
James S. Park, Neeraj Saraf, Douglas T. Dieterich. (2006) HBV plus HCV, HCV plus HIV, HBV plus HIV. Current Gastroenterology Reports 8:1, 67-74
CrossRef280
R. Manfredi. (2006) Coinfection with HIV and Hepatitis C Virus and Immune Restoration during HAART. Clinical Infectious Diseases 42:2, 298-299
CrossRef281
Jeanne Serpaggi, Marie-Laure Chaix, Dominique Batisse, Caroline Dupont, Anaïs Vallet-Pichard, Hélène Fontaine, Jean-Paul Viard, Christophe Piketty, Elisabeth Rouveix, Christine Rouzioux, Laurence Weiss, Stanislas Pol. (2006) Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 20:2, 233-240
CrossRef282
Annie Luetkemeyer, C Bradley Hare, John Stansell, Phyllis C Tien, Edwin Charlesbois, Paula Lum, Diane Havlir, Marion Peters. (2006) Clinical Presentation and Course of Acute Hepatitis C Infection in HIV-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 41:1, 31-36
CrossRef283
B. L. Pearlman. (2006) Hepatitis C Virus Infection in African Americans. Clinical Infectious Diseases 42:1, 82-91
CrossRef284
Ivanko Bojic, Ljubisa Dokic, Svetlana Minic. (2006) Treatment options for chronic hepatitis C virus infection. Medicinski pregled 59:11-12, 560-566
CrossRef285
F. Bani-Sadr, F. Carrat, E. Rosenthal, L. Piroth, P. Morand, F. Lunel-Fabiani, M. Bonarek, N. C. de Verdiere, G. Pialoux, P. Cacoub, S. Pol, C. Perronne, . (2005) Spontaneous Hepatic Decompensation in Patients Coinfected with HIV and Hepatitis C Virus during Interferon-Ribavirin Combination Treatment. Clinical Infectious Diseases 41:12, 1806-1809
CrossRef286
Vincent Soriano, Luz Martin-Carbonero, Ivana Maida, Javier Garcia-Samaniego, Marina Nuñez. (2005) New paradigms in the management of HIV and hepatitis C virus coinfection. Current Opinion in Infectious Diseases 18:6, 550-560
CrossRef287
Stephanie A. Santos, Nickolas Kontorinis, Douglas T. Dieterich. (2005) Management of chronic Hepatitis C virus in patients with HIV. Current Treatment Options in Gastroenterology 8:6, 433-441
CrossRef288
Alex Yui Hui, Joseph Jao-Yiu Sung. (2005) Advances in chronic viral hepatitis. Current Opinion in Internal Medicine 4:6, 548-554
CrossRef289
Arun Swaminath, Deanna L. Oliver, Andrew C. McNeil, Tarek I. Hassanein. (2005) The influence of hiv coinfection on the natural history of hcv infection. Current Hepatitis Reports 4:4, 131-137
CrossRef290
Lisa I Backus, Derek Boothroyd, Lawrence R Deyton. (2005) HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations. AIDS 19:Suppl 3, S13-S19
CrossRef291
Pyllis C. Tien. (2005) Management and Treatment of Hepatitis C Virus Infection in HIV-Infected Adults: Recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office1. The American Journal of Gastroenterology 100:10, 2338-2354
CrossRef292
Glenn J Wagner, Gery W Ryan. (2005) Hepatitis C virus treatment decision-making in the context of HIV co-infection: the role of medical, behavioral and mental health factors in assessing treatment readiness. AIDS 19:Suppl 3, S190-S198
CrossRef293
Victoria A Cargill. (2005) HIV/hepatitis C virus co-infection: its human face. AIDS 19:Suppl 3, S1-S2
CrossRef294
Mark S Sulkowski, David L Thomas. (2005) Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness. AIDS 19:Suppl 3, S8-S12
CrossRef295
Vanessa V Thompson, Kathleen E Ragland, Christopher S Hall, Maureen Morgan, David R Bangsberg. (2005) Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons. AIDS 19:Suppl 3, S208-S214
CrossRef296
Nickolas Kontorinis, Kaushik Agarwal, Douglas T Dieterich. (2005) Treatment of hepatitis C virus in HIV patients: a review. AIDS 19:Suppl 3, S166-S173
CrossRef297
R Peffault de Latour, T Asselah, V Lévy, C Scieux, A Devergie, P Ribaud, H Espérou, R Traineau, E Gluckman, D Valla, P Marcellin, G Socié. (2005) Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplantation 36:8, 709-713
CrossRef298
Alex Yui Hui, Joseph Jao-Yiu Sung. (2005) Advances in chronic viral hepatitis. Current Opinion in Infectious Diseases 18:5, 400-406
CrossRef299
Shruti H Mehta, David L Thomas, Mark S Sulkowski, Mahboobeh Safaein, David Vlahov, Steffanie A Strathdee. (2005) A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS 19:Suppl 3, S179-S189
CrossRef300
F. Legrand-Abravanel, F. Nicot, A. Boulestin, K. Sandres-Sauné, J.P. Vinel, L. Alric, Jacques Izopet. (2005) Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. Journal of Medical Virology 77:1, 66-69
CrossRef301
M. F. Miller, C. Haley, M. J. Koziel, C. F. Rowley. (2005) Impact of Hepatitis C Virus on Immune Restoration in HIV-Infected Patients Who Start Highly Active Antiretroviral Therapy: A Meta-analysis. Clinical Infectious Diseases 41:5, 713-720
CrossRef302
Yvonne C Gilleece, Rita E Browne, David Asboe, Mark Atkins, Sundhiya Mandalia, Mark Bower, Brian G Gazzard, Mark R Nelson. (2005) Transmission of Hepatitis C Virus Among HIV-Positive Homosexual Men and Response to a 24-Week Course of Pegylated Interferon and Ribavirin. JAIDS Journal of Acquired Immune Deficiency Syndromes 40:1, 41-46
CrossRef303
R. Jones, J. Dunning, M. Nelson. (2005) HIV and hepatitis C co-infection. International Journal of Clinical Practice 59:9, 1082-1087
CrossRef304
Scott K Fung, Anna S. F Lok. (2005) Update on viral hepatitis in 2004. Current Opinion in Internal Medicine 4:4, 359-366
CrossRef305
Norah J. Shire, Kenneth E. Sherman. (2005) Hepatitis C Virus in patients with inherited bleeding disorders. Current Hepatitis Reports 4:3, 87-91
CrossRef306
Gary L Davis, Karen L Lindsay. (2005) Treatment of chronic hepatitis C infection: one step at a time. The Lancet Infectious Diseases 5:8, 524-526
CrossRef307
N. J. Shire, K. E. Sherman. (2005) Clinical Trials of Treatment for Hepatitis C Virus Infection in HIV-Infected Patients: Past, Present, and Future. Clinical Infectious Diseases 41:Supplement 1, S63-S68
CrossRef308
G. W. Neff, N. J. Shire, S. M. Rudich. (2005) Outcomes among Patients with End-Stage Liver Disease Who Are Coinfected with HIV and Hepatitis C Virus. Clinical Infectious Diseases 41:Supplement 1, S50-S55
CrossRef309
M Nelson, G Matthews, MG Brook, J Main, . (2005) BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005). HIV Medicine 6:S2, 96-106
CrossRef310
Karen Weck. (2005) Molecular methods of hepatitis C genotyping. Expert Review of Molecular Diagnostics 5:4, 507-520
CrossRef311
E. M. Tedaldi. (2005) New Drug Targets for HIV and Hepatitis C Virus Coinfection. Clinical Infectious Diseases 41:Supplement 1, S101-S104
CrossRef312
Patrick Yachimski, Raymond T. Chung. (2005) Update on hepatitis B and C coinfection in HIV. Current Infectious Disease Reports 7:4, 299-308
CrossRef313
C. L. Cooper. (2005) Therapeutic Interventions for HIV Infection and Chronic Viral Hepatitis. Clinical Infectious Diseases 41:Supplement 1, S69-S72
CrossRef314
B Gazzard, . (2005) British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Medicine 6:S2, 1-61
CrossRef315
Tami Daugherty, Maurizio Bonacini. (2005) Therapy of hepatitis C in patients with HIV infection. Expert Review of Anti-infective Therapy 3:3, 375-384
CrossRef316
José M. Miró, Julián Torre-Cisneros, Asunción Moreno, Montserrat Tuset, Carmen Quereda, Montserrat Laguno, Elisa Vidal, Antonio Riveroa, Juan González, Carlos Lumbreras, José A. Iribarrena, Jesús Fortún, Antonio Rimola, Antonio Rafecas, Guillermina Barril, Marisa Crespo, Joan Colom, Jordi Vilardell, José A. Salvador, Rosa Polo, Gregorio Garrido, Lourdes Chamorro, Blanca Miranda. (2005) Documento de consenso GESIDA/GESITRA-SEIMC, SPNS y ONT sobre trasplante de órgano sólido en pacientes infectados por el VIH en España (marzo 2005). Enfermedades Infecciosas y Microbiología Clínica 23:6, 353-362
CrossRef317
Juan Julián González-García, Beatriz Mahillo, Susana Hernández, Raquel Pacheco, Sergio Diz, Paz García, Herminia Esteban, José Ramón Arribas, Carmen Quereda, Rafael Rubio, Jesús Díez, Santiago Moreno, Juan José Vázquez-Rodríguez. (2005) Estudio multicéntrico sobre prevalencia de las coinfecciones por virus de hepatitis, indicación de tratamiento de hepatitis crónica C y necesidad de trasplante hepático en pacientes infectados por el VIH en España. Estudio GESIDA 29/02-FIPSE 12185/01. Enfermedades Infecciosas y Microbiología Clínica 23:6, 340-348
CrossRef318
James S. Park, Neeraj Saraf, Douglas T. Dieterich. (2005) Antiviral therapy in the HCV-coinfected patient with HIV and/or HBV. Current Hepatitis Reports 4:2, 68-74
CrossRef319
Mark S Sulkowski. (2005) Therapy Insight: management of hepatitis C in patients coinfected with HIV. Nature Clinical Practice Gastroenterology & Hepatology 2:5, 223-231
CrossRef320
AH Mohsen, S Murad, PJ Easterbrook. (2005) Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London. HIV Medicine 6:3, 206-215
CrossRef321
Camilla S Graham, Annalee Wells, Tun Liu, Kenneth E Sherman, Marion Peters, Raymond T Chung, Atul K Bhan, Janet Andersen, Margaret James Koziel. (2005) Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS 19:8, 767-773
CrossRef322
Brian R. Edlin, Thomas F. Kresina, Daniel B. Raymond, Michael R. Carden, Marc N. Gourevitch, Josiah D. Rich, Laura W. Cheever, Victoria A. Cargill. (2005) Overcoming Barriers to Prevention, Care, and Treatment of Hepatitis C in Illicit Drug Users. Clinical Infectious Diseases 40:s5, S276-S285
CrossRef323
Catherine A. Fleming, Sheila Tumilty, Jessica E. Murray, David Nunes. (2005) Challenges in the Treatment of Patients Coinfected with HIV and Hepatitis C Virus: Need for Team Care. Clinical Infectious Diseases 40:s5, S349-S354
CrossRef324
Lynn E. Taylor. (2005) Delivering Care to Injection Drug Users Coinfected with HIV and Hepatitis C Virus. Clinical Infectious Diseases 40:s5, S355-S361
CrossRef325
P. Cacoub, S. Pol. (2005) Co-infection par le virus de l'immunodéficience humaine (VIH) et le virus de l'hépatite C (VHC) : épidémiologie, gravité, nouveaux aspects thérapeutiques. La Revue de Médecine Interne 26:4, 267-270
CrossRef326
M. Seydi, P. Morlat, F. Bonnet, J. Rambeloarisoa, N. Bernard, D. Lacoste, M. Bonarek, P. Trimoulet, R. Ramanampamonjy, M.-E. Lafon, M. Dramé, J. Beylot. (2005) Efficacité et tolérance de l'association interféron pégylé-ribavirine chez les patients co-infectés VIH-VHC en pratique clinique : étude observationnelle de 32 patients. La Revue de Médecine Interne 26:4, 280-287
CrossRef327
Benigno Rodriguez, David A. Bobak. (2005) Management of hepatitis C in HIV-infected patients. Current Infectious Disease Reports 7:2, 91-102
CrossRef328
Robert G. Gish, Nezam H. Afdhal, Douglas T. Dieterich, K. Rajender Reddy. (2005) Management of hepatitis C virus in special populations: Patient and treatment considerations. Clinical Gastroenterology and Hepatology 3:4, 311-318
CrossRef329
Adeel A Butt. (2005) Hepatitis C virus infection: the new global epidemic. Expert Review of Anti-infective Therapy 3:2, 241-249
CrossRef330
B. J. Thomson, R. G. Finch. (2005) Hepatitis C virus infection. Clinical Microbiology and Infection 11:2, 86-94
CrossRef331
Andri Rauch, Martin Egger, J??rg Reichen, Hansjakob Furrer. (2005) Chronic Hepatitis C in HIV-Infected Patients: Low Eligibility and Applicability of Therapy With Pegylated Interferon-?? Plus Ribavirin. JAIDS Journal of Acquired Immune Deficiency Syndromes 38:2, 238-240
CrossRef332
Glen Lutchman, Marc Ghany. (2005) Pushing the treatment envelope for chronic hepatitis C?is more necessarily better?. Hepatology 41:2, 234-236
CrossRef333
Shiela M. Strauss, Janetta M. Astone, Corrine Munoz-Plaza, Holly Hagan, Don Des Jarlais. (2005) Residential Substance User Treatment Programs as Venues for HCV Pharmacological Treatment: Client and Staff Perspectives. Substance Use & Misuse 40:12, 1811-1829
CrossRef334
Montse Laguno, José M.ª Sánchez-Tapias, Javier Murillas, Xavier Forns, José L. Blanco, Esteban Martínez, María Larrousse, Agathe León, Montse Loncá, Ana Milinkovic, José M. Miró, Felipe García, José M.ª Gatell, Josep Mallolas. (2005) Avances en el diagnóstico y tratamiento de la infección por el VHC en pacientes con y sin infección por el VIH. Enfermedades Infecciosas y Microbiología Clínica 23:1, 32-40
CrossRef335
Curtis L Cooper. (2005) Therapies for HIV and viral hepatitis coinfection. Expert Review of Anti-infective Therapy 3:1, 81-89
CrossRef336
S. Norah, J. K. Margaret. (2004) Prediction of Relapse following Treatment for Hepatitis C: Is Whole Blood More than the Sum of Its Parts?. Clinical Infectious Diseases 39:12, 1761-1763
CrossRef337
CHLOE L THIO. (2004) Chronic hepatitis B or C in HIV-infected persons: pathogenesis and management. Journal of Gastroenterology and Hepatology 19:s7, S138-S144
CrossRef338
John McHutchison, Amany Zekry. (2004) Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfected with HIV?. Nature Clinical Practice Gastroenterology & Hepatology 1:2, 70-71
CrossRef339
(2004) Peginterferon plus Ribavirin for Hepatitis C in HIV-Infected Patients. New England Journal of Medicine 351:22, 2340-2342
Full Text340
Pawlotsky, Jean-Michel, . (2004) Treating Hepatitis C in “Difficult-to-Treat” Patients. New England Journal of Medicine 351:5, 422-423
Full Text341
Alfredo Guarino, Eugenia Bruzzese, Giulio De Marco, Vittoria Buccigrossi. (2004) Management of Gastrointestinal Disorders in Children with HIV Infection. Pediatric Drugs 6:6, 347-362
CrossRef342
Greg L Plosker, Gillian M Keating. (2004) Peginterferon-??-2a (40kD) Plus Ribavirin. Drugs 64:24, 2823-2843
CrossRef
- Letters
